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ABSTRACT 
Chris Bernard Otieno Agala: Referral network factors and health outcomes among HIV-positive 
women in Ethiopia 
(Under the direction of Bruce J. Fried) 
 
Timely initiation, retention, adherence to antiretroviral therapy and improved quality of life 
among HIV-positive people are major goals of the UNAIDS Fast-Track or the 90-90-90 Initiative 
and the Ethiopian government. To contribute to these goals, MEASURE Evaluation implemented a 
referral network strengthening intervention in 2011-2012. The goal was to increase inter-
organizational referrals, access to HIV services, adherence and quality of life among 1046 HIV-
positive women receiving care from 51 providers in Addis Ababa, Ethiopia. Improvements in 
organizational network characteristics have been shown to improve health outcomes, yet pathways 
of these effects are poorly understood. Measurement invariance, a statistical property indicating that 
the same latent construct is being measured across groups, has also not been assessed. It is necessary 
for valid group comparisons of average latent outcome scores. 
The objective of this study was to assess measurement invariance of standardized adherence 
and quality of life scales across patient-groups. It also assessed effects of the intervention, improved 
referrals and patient-related factors on treatment delay and adherence. 
In this pre-post quasi-experimental and interventional study, adherence and quality of life 
were measured using the Simplified Medication Adherence Questionnaire and the World Health 
Organization Quality of Life-BREF questionnaires respectively. Multiple group confirmatory factor 
analysis was used to evaluate measurement invariance of the latent outcomes. Structural equation 
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modeling was used to evaluate the effects of the intervention on latent outcomes and direct and 
indirect effects between exogenous variables and the outcomes of interest. 
Findings suggest similarity in factor loadings, item intercepts and factor variances of 
observed responses for adherence (strong factorial invariance) but not quality of life (configural 
invariance) across intervention and control groups pre-and post-intervention. Patients in the 
intervention group were initiated on treatment 15 days earlier on average than those in control. The 
intervention had no effect on adherence. Quicker antiretroviral initiation improved adherence in the 
intervention site. Also, improved satisfaction increased adherence.  
Adherence scores can be compared across groups whereas those of quality of life cannot. 
Timely treatment initiation is a leverage facilitator of adherence. Referral network improvement is a 
necessary but insufficient factor for adherence, as depicted in the WHO’s adherence model. 
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 DISSERTATION OUTLINE CHAPTER 1.
 
Chapter 2 of this dissertation outlines the introduction of this work, discussing the background, 
significance, contribution and the conceptual model for the dissertation research presented in this 
work. It discusses the aims, objectives and hypotheses of this research and their motivation. It also 
outlines current peer-reviewed literature on measurement invariance of the standardized 
questionnaires of adherence and quality of life. Further, it outlines literature on adherence to ART, 
access to and delay in ART initiation in Ethiopia and other low-income sub-Saharan settings. 
Chapters 3 to 5 are complete manuscripts from my research on aims 1 to 3, each with introduction, 
methods describing: data source, study sample, study design, analytic approach, key independent, 
dependent and control variables, results and discussion sections.  
 
In the first aim, Chapter 3 in this dissertation, I assessed measurement models of adherence and 
QOL. The objective of this aim was to assess the extent to which the same intended latent 
constructs were measured across time and between groups, to allow for valid comparisons of 
average levels of the outcomes across study groups and time points, finding that average levels of 
adherence could be compared whereas those of QOL could not. Due to this finding, I excluded the 
measurement model for QOL in the subsequent path analyses for my second and third aims, 
presented in Chapter 4 and Chapter 5 respectively. The second aim explored an intermediate and 
traditionally evaluated model for adherence. It assessed the effects of the intervention and patient-
level factors on adherence levels among patients in the four study groups. The third aim explored 
my hypothesized full model for adherence, based on the variables at hand. It examined the total, 
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direct and indirect effects on delay in ART initiation and adherence of the referral network as well as 
patient factors. 
 
Chapter 6 discusses abstracts for aims 1 to 3 or Chapters 3 to 5, knowledge gaps and future 
directions, implications for policy and practice and overall conclusions.  
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 INTRODUCTION CHAPTER 2.
 
2.1 Background 
The Joint United Nations Program on HIV/AIDS (UNAIDS) estimates that 590,000 Ethiopians 15 
years or older were living with HIV by the end of 2013 (UNAIDS, 2014). The WHO estimates 
urban HIV prevalence rate in Ethiopia at eight percent, compared to a much lower rural rate of one 
percent (WHO, 2017). In Ethiopia, HIV treatment and care services are provided free of charge at 
public health facilities and non-profit organizations in Ethiopia through the support of the 
government and several international development partners. Despite availability of free treatment, 
40 percent of all patients who need antiretroviral therapy (ART) do not have access (WHO, 2017). 
The reported rate of access to ART is higher in Ethiopia compared to an estimated 50 percent 
average for the rest of Africa (WHO, 2017). Despite major improvements, which have increased 
access to ART in the last decade, challenges such as insufficient drugs, drug stock-outs, lack of trust 
on treatment, lack of HIV service points, limited drug stocks and fragmented and siloed HIV 
services, have led to lack of universal access to ART (Stange, 2009; IOM , 2013). Services needed by 
HIV-positive patients such as: antiretroviral and opportunistic infection drugs, counseling, 
psychosocial support and nutritional services, among others, are often provided by different 
providers in different locations. Fragmentation of health services without coordination and 
integration is associated with wastage of resources and inefficiencies in provision of care, which 
adversely affect access and quality of care (Berwick, 2011).  
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Organizational referral network strengthening has been identified as a strategy to improve 
integration and coordination of care. A referral network expands treatment and care opportunities 
for patients because it increases the pool of services available for patients. An organizational referral 
network is a group of health service providers within a defined geographical location. Both the U.S 
Global Health Initiative and The President’s Emergency Plan for AIDS Relief (PEPFAR) promote 
comprehensive or appropriate range of services, integration and coordination as key strategies in 
HIV care (PEPFAR, 2014). Increasing access to and retention of HIV patients on ART are major 
goals of the Ethiopian government and UNAIDS FastTrack Initiative. The FastTrack Initiative has 
90-90-90 targets for 2020 and 95-95-95 for 2030. The initiative aims to test 90 percent of all HIV 
infected individuals, initiate and retain 90 percent of those tested on ART and achieve HIV viral 
suppression among 90 percent of those receiving ART by 2020, and corresponding targets for the 
95-95-95 strategy by 2030. 
 
To test the effect of network strengthening interventions on integration and coordination of care, 
USAID funded a quasi-experimental study among 1046 women 18-49 years old in two non-
contiguous HIV treatment referral networks in Addis Ababa between 2011 and 2012 (Thomas J. , 
Reynolds, Bevc, & Tsegaye, 2014). The first part of the study assessed the baseline level of inter-
organizational interaction and coordination between the 51 health facilities and organizations in 
both networks and found low levels of interaction (defined as “low network density”). Following the 
finding, an intervention was implemented, consisting of three two-day meetings with referral training 
and coaching, development and distribution of service directories and contact information to 25 
organizations in the intervention network. The intervention resulted in a significant improvement in 
network density in the intervention compared to control group of 26 facilities (Thomas J. , 
Reynolds, Bevc, & Tsegaye, 2014). Thomas and colleagues also found positive associations between 
5 
 
network density and patient satisfaction with care in the intervention group (Thomas J. , Reynolds, 
Alterescu, Bevc, & Tsegaye, 2015). Various studies have also shown positive associations between 
network-level characteristics and improvements in patient-reported health outcomes (Provan & 
Milward, 2001; Morrissey, Tausig, & Lindsey, 1985; Provan, Veazie, Teufel-Shone, & Huddleston, 
2004; Thomas, Isler, Carter, & Torrone, 2007; McKinney, Morrissey, & Kaluzny, 1993; Thomas, 
Isler, Carter, & Torrone, 2007).  
 
Whereas the findings by Thomas et al. (2014, 2015) and other authors have shown global network 
improvements to be significant for HIV care, no research has studied direct and indirect effects of 
referral networks on patient-reported health outcomes. It is important to study direct and indirect 
effects in order to reveal the mechanism through which referral network characteristics affect patient 
health outcomes. A direct effect is defined as a relationship between a measured and latent or 
unmeasured variable, whereas an indirect effect “is the relationship between an independent latent 
variable and dependent latent variable that is mediated by one or more latent variables” (Weston, 
2006; Bollen, 2002). Previous studies have focused on understanding the characteristics and 
structure of organizational networks and their total effects on health outcomes. Thus, it is not clear 
from those analyses exactly how inter-organizational level network structure produced patient-level, 
satisfaction with HIV care, effects. These studies did not seek to identify the direct and indirect 
effects linking network structure to satisfaction.  
 
In addition, accurate measurement is critical for effective national policy-wide formulation. It is 
common practice for researchers and interventionists to make comparisons of levels of latent 
outcomes between patient groups; (e.g., intervention and control, rural and urban, or male and 
female), yet standardized questionnaires for collecting such data may not have been tested for 
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measurement invariance. Measurement invariance is a statistical test of standardized questionnaires 
for assessing whether the same intended latent construct is measured across all groups being 
compared (Wicherts, 2016). The standardized questionnaires for adherence and quality of life (QOL) 
which were used in the parent study have not been tested for measurement invariance. This 
dissertation research addresses these knowledge gaps. It examined measurement invariance of the 
adherence and QOL questionnaires in the first aim; and direct and indirect pathways between 
referral network- and patient-level factors and patient-reported health outcomes – treatment delay 
and adherence.  
 
The long-term goal of this research was to contribute to improvement of access to and retention of 
patients on HIV treatment in Ethiopia. The aim of this study was to identify the pathways through 
which patient- and organizational-level factors and referral network characteristics affect health 
outcomes. My central hypothesis was that measurement invariance testing of the standardized 
questionnaires of adherence and QOL and assessment of direct and indirect effects of the network 
are important for comprehensive HIV care policy formulation. I tested my central hypothesis by 
pursuing the following specific aims:  
 
1) To assess measurement invariance of these two latent patient-reported health outcomes 
using multiple group confirmatory factor analysis with data from HIV positive patients who 
were receiving treatment in two treatment networks in Ethiopia. 
 
Hypothesis: I hypothesized that sample covariance matrices (factor loadings, variances, and 
covariances) for QOL and adherence would be equal across the four groups –  time 1 or 
“T1” control, T1 intervention, time 2 or “T2” control and T2 intervention. 
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2) To assess the effect of referral network characteristics as well as patient’s age, income, 
marital status and education on patient-reported ART adherence using structural equation 
models. 
 
3) To assess the effect of referral network characteristics as well as patient’s age, income, 
marital status and education on patient-reported delay in ART initiation, and the effect of 
satisfaction with HIV/AIDS care and delay in ART initiation on adherence using structural 
equation models. 
 
Hypothesis for the second and third aims: I hypothesized that all patient-level factors would 
have significant positive effects on ART adherence. In addition, I hypothesized that the 
intervention would increase adherence and reduce delay in ART initiation, and that 
enhanced speed of ART initiation would increase adherence in the intervention network 
compared to the control network at T2. Further, I hypothesized that delay in ART initiation 
would have a direct effect on adherence, and that it would mediate the direct and indirect 
effects of referral network density and patient-level factors on adherence. 
 
These hypotheses were based on the WHO’s five-dimension model of access to ART and treatment 
adherence (see Figure 2.1). In addition, they were based on Anderson’s healthcare utilization model 
(see Figure 2.2), previous publications from the parent study, and literature on the associations 
between improved referral network density and treatment delay and adherence (Andersen R. , 1995; 
WHO, 2003; Thomas J. , Reynolds, Bevc, & Tsegaye, 2014; Thomas J. , Reynolds, Alterescu, Bevc, 
& Tsegaye, 2015).  
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2.2 Significance and contribution 
The wider significance of this study is that it will inform future data collection, analysis, 
interpretation and comparability of results in studies assessing similar latent constructs to inform 
planning and policy development for improved treatment and patient outcomes. In addition, this 
study identified the effects of network density and patient characteristics on delay in ART initiation 
and adherence. It also related the findings to the contexts of the organizations in the network that 
received the intervention. Network density is defined as the number of organizational interactions as 
a proportion of the potential total. This contribution is significant because understanding these 
relationships will facilitate design of targeted and tailored HIV treatment interventions that 
contribute to the WHO’s five-dimension multi-level factors of adherence described in Figure 2.1, 
quicken ART initiation, and improve treatment retention among HIV patients. These are all goals of 
the Ethiopian government and the UNAIDS Fast-Track Initiative (Stover, et al., 2016; UNAIDS, 
2014).  
 
Interventions to improve uptake of, retention on, and adherence to ART and to improve QOL are 
important for better HIV-patient outcomes. However, few studies have used the WHO framework 
(see Figure 2.1) and network analysis tools to examine existing systems for HIV care yet there is 
interest among policy-makers, service providers and patients to improve accessibility and efficiency 
of services (Kwait, Valente, & Celentano, 2001; WHO, 2003). Kwait and colleagues (2001) reported 
that studying the impact of inter-organizational linkages and network structure on patient outcomes 
remained an important but understudied area (Kwait, Valente, & Celentano, 2001). The WHO has 
also reported a paucity of research evaluating the multi-level factors that determine adherence 
(WHO, 2003). They reported that due to variations in local responses to HIV, network analysis 
studies were necessary in different socioeconomic environments (WHO, 2003). In the parent study, 
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Thomas et al. (2015) found direct heterogeneous effects on patient satisfaction with care among 
patients receiving care from a high density compared to a low density referral network (Thomas J. , 
Reynolds, Alterescu, Bevc, & Tsegaye, 2015). Despite prior studies on service delivery networks, 
none has looked at pathways through which they affect patient outcomes, which has led to poor 
understanding of these processes. This study examined relationships between referral networks and 
patient characteristics as predictors, and treatment delay and adherence as outcomes, with the intent 
to inform the design of interventions to improve these outcomes in the populations studied. 
 
This study identified the direct and indirect effects of HIV referral networks and patient 
characteristics on delay in ART initiation and adherence, and related these findings to the contexts 
of the organizations in the network that received the intervention. The goal was to increase patient 
access, retention and adherence to ART, which are priorities for the Ethiopian government and the 
international community (UNAIDS, 2014). Improved health outcomes will reduce socioeconomic 
disease burden for affected families and the government and ensure return on HIV/AIDS 
investments by local communities, the local and global public health community.  
 
In Ethiopia, average retention of patients on HIV treatment has been estimated to be 70 percent, 
whereas average adherence rates are reported to be 51-85 percent (Bezabhe W. , Peterson, 
Bereznicki, Chalmers, & Gee, 2013; MOH, Ethiopia, 2014). In addition, a meta-analysis of 27 
studies, conducted in 12 sub-Saharan Africa countries (excluding Ethiopia), found an average 
adherence rate of 77 percent among study participants who were on antiretroviral therapy (Mills, et 
al., 2006). Further, in the same meta-analysis, the authors reported average adherence of 55 percent 
among patients who participated in 24 studies in the United States and Canada (Mills, et al., 2006). 
These levels are below the 95 percent or higher level required for antiretroviral drug effectiveness 
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(Paterson, et al., 2000; Ickovics, et al., 2002; UCSF, 2017; Bezabhe W. , Peterson, Bereznicki, 
Chalmers, & Gee, 2013). Antiretroviral therapy can improve functionality and QOL of HIV patients 
and decrease mortality, but lapses in adherence may render treatment ineffective (Catz, Kelly, 
Bogart, Benotsch, & McAuliffe, 2000). Non-adherent patients have higher mortality rates than 
adherent ones with similar CD41 counts and adherence is the critical determinant of survival among 
HIV+ patients (Wood, et al., 2003; AIDS.gov, 2014). 
 
The positive contribution of this study is to facilitate an improved understanding of the ways in 
which referral networks and patient-related factors influence delay in ART initiation, adherence and 
QOL and the organizational contexts in which these relationships thrive. In addition, the study 
enhances our understanding of the relationships between these patient-reported health outcomes in 
this population sample. This knowledge can contribute to improving HIV/AIDS outcomes among 
patients by designing appropriate interventions in future programs. 
 
2.3 Conceptual Model 
A theoretical framework was necessary in order to bring empirical evidence to bear on treatment 
delay and medication adherence among patients and how they can be improved. For this purpose, I 
used Andersen and Aday’s healthcare utilization and the WHO’s adherence models (Andersen R. , 
1995; WHO, 2003). Andersen’s model has four domains: healthcare environment, population 
characteristics, health behavior and health outcomes. Andersen’s model theorizes that the healthcare 
environment consists of the healthcare system comprising health policies, regulations and 
characteristics of health service providers. In addition, it posits that population characteristics 
include: predisposing, enabling and need factors. Finally, it posits that the environment influences 
                                                 
1 CD4 is a type of white blood cells that play a major role in protecting the body from infection. 
11 
 
predisposing and enabling patient-level factors, which influence personal health practices and use of 
health services that eventually determine patient health outcomes (Andersen R. , 1995). Andersen’s 
model posits that a set of factors contribute to people’s use of healthcare services. These factors 
include: predisposition of individual patients to use healthcare services, (indicated by demographic 
and social factors and beliefs of patents about health services - also known as individual 
predisposing factors, under the population characteristics domain), ability to access healthcare 
services (indicated by personal resources and availability of healthcare services within the community 
where patients live - also known as enabling factors), and the patient’s state of illness (as self-
perceived by the patient and evaluated by a healthcare expert who provides treatment and other 
services -also known as need) (see Figure 2.2) (Andersen & Aday, 1978). The WHO’s adherence 
model applies the Andersen’s model by positing that adherence is influenced by healthcare team and 
system-related, condition-related and patient-related factors and characteristics of therapy. 
 
In this dissertation, individual predisposing and social factors included: patient’s age, marital status 
and income. Enabling factors were categorized into two parts: individual and organizational. 
Individual enabling factors included patient’s income, whereas organizational enabling factors 
included organizational budget, number of staff, type of organization and network density. I did not 
include organizational enabling factors in my analysis because there was no variable linking patients 
to their main provider in their HIV care network. I also excluded need factors in this dissertation as 
there were none in the data set. Individual predisposing and social factors and individual and 
organizational enabling factors were included because of their hypothesized direct and indirect 
effects on treatment delay and adherence. Andersen and Aday described mutability as the extent to 
which a factor can be altered to influence distribution of health services (Andersen & Aday, 1978). 
Based on this concept, predisposing factors are difficult to target using policy interventions because 
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they are largely immutable. However, enabling factors are mutable and can thus be targeted for 
policy interventions. Enabling factors such as patient’s income, organizational budget, number of 
staff, type of organization and network density can be more easily targeted for intervention to 
favorably impact treatment delay and adherence among patients in a given HIV treatment network. 
 
In this dissertation, I investigated the direct and indirect effects of individual predisposing and 
enabling financing and organizational factors on treatment delay and medication adherence. I 
included age, years of education and marital status as individual predisposing and social factors; 
income as an individual enabling financing factor. However, due to the limitation described above 
about enabling organizational factors (budget, type of organization and number of healthcare 
professionals), I only discussed my findings and conclusions in the context of these characteristics in 
the intervention compared to control referral networks at T1 and T2.  
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 MEASUREMENT INVARIANCE OF HIV TREATMENT ADHERENCE CHAPTER 3.
AND QUALITY OF LIFE SCALES AMONG HIV POSITIVE WOMEN IN 
ETHIOPIA 
 
3.1 Introduction 
According to the United Nations AIDS Program (2016) report, more than 36 million people were 
living with HIV/AIDS, of whom 17 million were on antiretroviral therapy (ART) by the end of 
2015 (UNAIDS, 2016). HIV treatment using antiretroviral therapy can improve functionality and 
decrease mortality but lapses in adherence may render treatment permanently ineffective, for 
example, due to drug resistance (Catz, Kelly, Bogart, Benotsch, & McAuliffe, 2000). The WHO has 
defined adherence as “the extent to which a person’s behavior – taking medication, following a diet, 
and executing lifestyle changes, corresponds with agreed recommendations from a healthcare 
provider” (WHO, 2003). Non-adherent patients have higher mortality rates than adherent ones with 
similar CD4+2 counts and adherence is the critical determinant of survival among HIV positive 
patients (Wood, et al., 2003; AIDS.gov, 2014). Non-adherence is also associated with poor health 
outcomes, increased healthcare costs and poor patient safety, due to increased risk of dependence, 
relapses, toxicity, to mention a few (WHO, 2003). Adherence is reported to be a major challenge in 
healthcare, estimated at 50 percent in high-income countries and even lower in some low and 
medium income countries (LMICs) (WHO, 2003). In Ethiopia, adherence and retention on 
treatment were estimated to average 51-85 percent and 70 percent respectively (Bezabhe W. , 
Peterson, Bereznicki, Chalmers, & Gee, 2013). In addition, a meta-analysis of 27 studies, which were 
conducted in 12 sub-Saharan Africa countries (excluding Ethiopia), found average adherence rates 
                                                 
2 CD4 is a type of white blood cells that play a major role in protecting the body from infection. 
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of 77 percent among study participants who were on antiretroviral therapy (Mills, et al., 2006). 
Further, in the same meta-analysis, the authors reported average adherence of 55 percent among 
patients who participated in 24 studies in the United States and Canada (Mills, et al., 2006).  
 
Accurate measurement of adherence is important for accurate assessment of health outcomes and in 
predicting antiretroviral treatment efficacy (WHO, 2003). Nonadherence compromises treatment 
efficacy, and without accurate treatment efficacy data, adherence rates necessary for planning and 
project evaluation cannot be achieved (WHO, 2003). Further, accurate measurement of adherence is 
required for effective and efficient treatment planning, and for ensuring that changes in health 
outcomes can be attributed to recommended regimens. In addition, decisions to change 
recommendations, medications, and/or communication style in order to promote patient 
participation depend on valid and reliable measurement of the adherence construct (WHO, 2003). 
However, there is no “gold standard” for measurement in adherence. One approach, which has 
been used, is to ask patients for subjective ratings of their adherence behavior. The World Health 
Organization has reported that the analysis of patient reports of adherence collected using this 
approach is problematic (WHO, 2003). It also reported that there are challenges in measurement of 
the adherence construct even when more objective methods are used.  Examples include:  
 counting inaccuracies using the “remaining dosage units” method  
 the inability to capture important information such as timing of dosage and pattern of 
missed dosage 
  the high cost of medication event monitoring systems (MEMS)  
 the inability to tell whether patients actually use their medicine when they are removed from 
the bottle 
 difficulties faced when an individual acquires medication at multiple pharmacies 
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 inaccurate and incomplete records using the pharmacy refills method (WHO, 2003).  
Further, it was reported that patients who revealed that they had not followed treatment advice from 
their healthcare provider tended to give more accurate reports of their adherence behavior, and vice 
versa (WHO, 2003). Whereas there are no personality traits that reliably predict adherence, 
standardized questionnaires that assess specific behavior relating to medication recommendations 
may be better predictors (WHO, 2003). 
 
Several studies have assessed and found positive bidirectional associations between adherence and 
QOL (Bader, et al., 2006; Bonjoch, et al., 2005; Chiou, Kuo, Lee, Chen, & P Chuang, 2006; Jia, et al., 
2004; Luszczynska, Sarkar, & Knoll, 2007; Mannheimer, et al., 2005; Parsons, Braaten, Hall, & 
Robertson, 2006; Patrick & Erikson, 1988; Ruiz-Pérez, et al., 2005; Sherr, et al., 2007). A systematic 
review of the literature on QOL and adherence among HIV positive patients who were on 
antiretroviral medication concluded that on average, high adherence rates were associated with 
increased QOL (Geocze, Mucci, Marco, Nogueira-Martins, & Citero, 2010). According to the 
authors, mixed results about the associations between adherence and QOL were found when: 
patients experienced side effects due to high adherence rates, asymptomatic patients experienced 
little or no improvement on their QOL and patients were bothered by reduced privacy in social 
situations due to noisy adherence reminders (Geocze, Mucci, Marco, Nogueira-Martins, & Citero, 
2010).  
 
Quality of life is a common measure of health status (Parrish, 2010; Dominick, Ahern, Gold, & 
Heller, 2002). The WHO defines quality of life (QOL) as “a person’s perception of his/her position 
in life within the context of the culture and value systems in which he/she lives and concerns” 
(WHOQOL Group, 1994).  Accurate measurement of QOL across time and groups is important for 
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healthcare service policy-makers and providers. However, measurement of quality of life faces 
similar challenges as patient-reported adherence because data are limited to subjective patient 
perceptions of health status.   
 
While standardized questionnaires or scales such as AACTG3, CASE4, SMAQ, ODI5, SF36 PFD6, 
PROMIS PFD7, among others, have potential advantages in understanding perceptions about pain, 
adherence, QOL and physical functioning, literature assessing measurement invariance of different 
scales in multiple settings is sparse. In addition, standardized scales are often used with populations 
that may be quite different from the one in which the scales were validated (Bialosiewicz, Murphy, & 
Berry, 2013). Thus, it is common for users to begin with validated scales and modify them to fit 
evaluation context and participant populations. Our ability to assess true differences between groups 
or across time can be hindered by measurement errors, which can limit our ability to make accurate 
meaningful comparisons when determining program impact (Bialosiewicz, Murphy, & Berry, 2013). 
Constructs of interest such as adherence and QOL are commonly measured using multi-indicator 
scales. Each indicator used in the scale on its own is insufficient to capture the construct, but when 
these items are combined, they represent a valid indirect composite measure of the construct of 
interest (Bialosiewicz, Murphy, & Berry, 2013). Therefore, in addition to reliability and validity tests, 
I performed measurement invariance to assess whether respondents interpreted measures 
                                                 
3 Adult AIDS Clinical Trials Group (AACTG) instrument (Chesney et al., 2000) 
4 Center for Adherence Support Evaluation (CASE) Adherence Index. S. B. Mannheimer, R. Mukherjee, L. R. 
Hirschhorn, J. Dougherty, S. A. Celano, D. Ciccarone, K. K. Graham, J. E. Mantell, L. M. Mundy, L. 
Eldred, MichaelBotsko, and R. Finkelstein. 
 
5 Oswestry Disability Index (ODI) for lumbar spinal disorder 
6 SF-36 Physical function domain 
7 PROMIS physical function domain 
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conceptually similarly across groups and time and whether participation in an intervention altered 
the conceptual frame of reference against which a group responded to an indicator over time 
(Bialosiewicz, Murphy, & Berry, 2013).  
Assessment of measurement invariance of standardized scales helps in determining if the scale 
functions equivalently for all groups, which can be defined by such factors as gender, age, education, 
mother tongue, socioeconomic status, regional background, among others (Wicherts, 2016). 
Measurement invariance requires that two persons with the same level of latent construct should 
obtain the same expected score on the indicators used to measure the underlying construct, 
regardless of the group they are in (Wicherts, 2016). This study assessed the measurement 
invariance8 of two standardized scales, which were used to compare pre-and post-intervention 
differences in measures of QOL and adherence among 1046 HIV positive patients from two HIV 
treatment networks in Addis Ababa, Ethiopia. The World Health Organization Quality of Life – 
HIV 31 BREF (WHOQOL - HIV 31-BREF) measured QOL (see Appendix 1), whereas the 
Simplified Medication Adherence Questionnaire (SMAQ) measured adherence (see Appendix 2) 
(WHO, 2002; Thomas J. , Reynolds, Bevc, & Tsegaye, 2014). 
 
In such intervention projects, there is a natural desire to make group comparisons and conclusions 
about the effect of the intervention on the mean scale scores of expected patient outcomes (Sousa, 
West, Moser, Harris, & Cook, 2012 ). However, such comparisons are justified to the extent that 
psychometric performance indicates these comparisons approximate differences of means on the 
theoretical true score of the relevant constructs (Sousa, West, Moser, Harris, & Cook, 2012 ). 
Further, inferences and conclusions about the observed mean differences are dependent on the 
                                                 
8 Measurement invariance or measurement equivalence is a statistical property of measurement that indicates that the 
same construct is being measured across some specified groups. 
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between–group equivalence of the underlying measurement model and a comparison between 
groups, even when standardized scales such as SMAQ and WHOQOL HIV BREF are used (Sousa, 
West, Moser, Harris, & Cook, 2012 ).  
 
Evaluating measurement invariance is a statistical approach that is used to assess the extent to which 
a scale such as SMAQ and WHOQOL HIV measures the same construct in all of the groups and 
across all relevant time points (Sousa, West, Moser, Harris, & Cook, 2012 ). This allows us to make 
valid comparison of construct scores that yield meaningful interpretations and substantive inferences 
(Vandenberg & Lance, 2000). SMAQ was developed by the Centers for Disease Control and 
Prevention for assessment of HIV treatment adherence among patients who are using anti-retroviral 
medicine (CDC, 2013), whereas WHOQOL HIV 31 BREF was developed as a cross-cultural 
instrument for assessment of quality of life among people living with HIV. The WHOQOL HIV 
has been validated for use in Ethiopia in a study that found it appropriate for use there and in similar 
settings (Tesfaye, et al., 2016). However, there has been no study conducted to assess its 
measurement invariance in these or similar settings across different groups at different time points. 
Similarly, SMAQ has been validated for use by studies which assessed its appropriateness for use 
among HIV positive patients and patients with renal disease in Spain. However, no studies have 
assessed its measurement invariance in sub-Saharan Africa region or in similar settings (Knobel, et 
al., 2002; Suárez, et al., 2011). 
 
According to the WHO, adherence to treatment is affected by five interrelated factors: (1) socio-
economic factors; (2) healthcare team and system factors; (3) condition-related factors; (4) therapy-
related attributes; and (5) patient characteristics (WHO, 2003). Healthcare team and health-system-
related factors constitute the healthcare environment in which patients receive care. These factors 
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include providers’ schedules, length of appointments, allocation of resources, fee structures, 
communication and information systems, and organizational priorities (WHO, 2003). These factors 
have the potential to support or inhibit access to care (WHO, 2003). Thus, factors at multiple levels 
have the potential to affect adherence. In turn interventions targeting improved adherence must 
address these determinants of adherence (WHO, 2003). Further, ignoring these variables can limit 
the impact of the efforts of providers and patients (WHO, 2003).  
 
The present research builds off of parent organizational referral network study conducted in 
Ethiopia in 2011-2012 that collected multi-level data on two of the five dimensions of adherence 
and QOL as part of an HIV intervention effort in two communities. To date, the psychometric 
properties of the adherence and QOL measures used in this study have not been examined.  
 
The objective of the present study was to assess whether the same latent constructs of treatment 
adherence and quality of life were measured across two patient groups at two time points. Its aim 
was to assess measurement invariance of these two latent patient-reported health outcomes using 
multiple group confirmatory factor analysis with data from HIV positive patients who were 
receiving treatment in two treatment networks in Ethiopia. I hypothesized that sample covariance 
matrices (factor loadings, variances, and covariances) for QOL and adherence would be equal across 
the four groups – T1 control, T1 intervention, T2 control and T2 intervention. The results of this 
study will assist the parent study in reporting the comparability of its between-group and across-time 
measures of adherence and QOL in future publications. In addition, the next two aims will apply 
these measurement models in path analyses and structural equation modes to assess associations 
between patient- and network characteristics and delay in ART initiation, adherence and QOL.  
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3.2 Methods 
This study was based on data from two cross-sectional surveys collected by MEASURE Evaluation 
as part of a quasi-experimental referral network study involving 1046 HIV-positive women who 
were receiving HIV care from 51 facilities in two non-contiguous sub-locations in Addis Ababa, 
Ethiopia in March 2011 – December 2012 (Thomas J. , Reynolds, Bevc, & Tsegaye, 2014). In 
addition to information on referral networks, data were also obtained on participants’ personal and 
household-level characteristics. Referral network facilities were identified using snowball census 
methodology, resulting in 25 facilities in Kirkos and 26 in Kolfe Keranyo (see Figure 3.1). Kirkos 
and Kolfe-Keranyo were designated intervention and control sub-cities respectively. To obtain 
referral network data, baseline (hereinafter referred to as Time 1 or “T1”) and follow-up (hereinafter 
referred to as Time 2 or “T2”) interviews were conducted with nominated key informants in each 
health facility about HIV services and the nature and types of referrals offered, organizational 
characteristics, collaborations, joint programs and linkages with other facilities.  
 
In addition to interviews with nominated knowledgeable organizational representatives, 459 and 587 
patients receiving care from either sub-cities were randomly selected and interviewed at T1 (March 
2011) and T2 (December 2012) respectively, to obtain information about their personal and 
household characteristics. Of the 459 patients at T1, 234 were from Kirkos whereas 225 were from 
Kolfe-Keranyo. Similarly, 293 and 294 patients at T2 were from Kirkos and Kolfe-Keranyo 
respectively. In the patient interviews, patients were asked about personal and household-level 
demographic characteristics; HIV care services needed and received, HIV treatment status, quality of 
life, satisfaction with care and medication adherence. The referral network strengthening 
intervention involved a series of three meetings held at different times in the intervention network 
after T1 data collection in Kirkos. Twenty-one out of the 25 organizations participated in at least 
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one of the meetings. Participants were nominated organizational officials with knowledge about 
HIV services offered and internal organizational characteristics. During the meetings participants 
learned about strategies for referral of patients, collaboration, joint programming and partnership 
with other organizations within the intervention network. They also learned about services offered 
by various facilities in the network. Service directories were also developed and shared, with each 
participating facility receiving at least one directory. A service directory is a list of organizations, their 
contact information and the services they offer. No intervention was implemented in Kolfe Keranyo 
-- the treatment network designated as control. Post-intervention interviews for T2 data were 
conducted 18 months after T1 using the same questionnaires that were used at T1 (see Figure 3.2). 
Some patients likely participated in both T1 and T2 interviews, but it was impossible to identify 
them due to anonymization. Participation in T2 was not conditional on T1 participation, the samples 
were thus essentially independent cross-sections. Table 3.1 contains summary data for the study 
sample. 
 
Key variables and measures 
Two underlying latent constructs of adherence and QOL were the dependent variables. They were 
both analyzed as continuous latent outcomes. A latent variable is an unmeasured factor, an 
unobserved construct or an indirectly measured factor, which is seen as the underlying cause of the 
performance on the indicators of adherence and QOL (Wicherts, 2016). The two latent constructs 
were measured using indicators that represent the underlying construct, as described below (Bollen, 
2002).  
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Measurement of patient medication adherence 
Patient adherence was assessed among participants who reported using antiretroviral medicine. They 
were asked six questions from a standardized scale known as Simplified Medication Adherence 
Questionnaire (SMAQ) (See Appendix 2) (CDC, 2013), as follows: “1. Do you ever forget to take 
your medicine?”, “2. Are you careless at times about taking your medicine? “3. Sometimes if you feel 
worse, do you stop taking your medicines? “4. Thinking about the last week, how often have you 
not taken your medicine?” “5. Did you not take any of your medicine over the past weekend? And, 
“6. Over the past three months, how many days have you not taken any medicine at all? A “yes” 
response to questions 1, 2, 3 and 5 constituted non-adherence whereas values >0 for question 4 and 
values >2 for question 6 constituted non-adherence. For analysis, the values were flipped such that 
“no”, zero days and ≤2 days constituted adherence (coded as 1, whereas nonadherence was codded 
0) for questions 1, 2, 3 and 5, 4 and 6 respectively.  
 
Measurement of health-related quality of life (QOL) 
To assess QOL, respondents were asked to rate their quality of life based on 31 questions from the 
WHOQOL - HIV 31-BREF (WHO, 2002) (Appendix 1). WHOQOL-HIV 31-BREF is a 
standardized scale for measuring quality of life among HIV/AIDS patients. It assesses an 
individual’s perception of quality of life based on six domains: physical, psychological, level of 
independence, social relationships, environment and spirituality, religion or personal beliefs. 
Individual items in the domains were rated on a 5-point Likert scale where 1 indicated low or 
negative perceptions and 5 indicated high or positive perception. Positive domains were scaled in a 
positive direction, where higher scores reflected better QOL. Negative domains such as pain, 
discomfort and negative feelings were scaled in a negative direction and were thus recoded so that 
higher scores reflected better QOL. Scores from the 31 items were then summed for an individual 
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and facets, defined by the WHO as areas of life considered relevant to assessment of QOL9, were 
scored through summative scaling whereby each item contributed equally to the facet score. Mean 
scores were then calculated by dividing the sum for each facet by 4. To calculate the domain scores 
the mean of the facet was computed by finding the average score and multiplying by 4 so that the 
final QOL domain scores were between 4 and 20 (WHO, 2002).  
 
Measurement Models 
Measurement models were used to evaluate how well the observed indicators for quality of life and 
adherence combined to identify the underlying latent constructs of QOL and adherence. 
Confirmatory factor analysis (CFA) was used to test the measurement models. The stronger the 
correlation between the indicators used to measure a latent variable, the higher the accuracy of the 
definition of the latent variable. Inclusion of a variable with weak or negative correlation may lead to 
misspecification or misjudgment of the hypothesized model.  
 
In the measurement model below, the latent variable, adherence, is measured with six factor 
indicators, q801- q806 (see Figure 3.3). Likewise, in the measurement model for QOL (see Figure 
3.4), the latent variable is measured using six factor indicators. Epsilons 1-6 represent indicator 
measurement errors in each model. The two latent factors of adherence and QOL re represented in 
oval shapes. The arrows are factor loadings, and represent direct effects of the indicators on the 
latent variables. 
 
 
                                                 
9 Examples of QOL facets for physical health domain: activities of daily living, dependence on medicinal substances and 
medical aids. Psychological domain: bodily image and appearance, negative feelings, positive feelings, self-esteem, etc. 
26 
 
Confirmatory factor analysis 
I used multiple group confirmatory factor analysis (CFA) to test my hypotheses. Multiple group 
CFA was chosen because the four groups (T1 control, T1 intervention, T2 control and T2 
intervention— (see Table 3.1) were considered to be independent. Under multiple group CFA, 
separate group-specific factor models were simultaneously tested. Similar models were fitted for 
each group and a chi-square difference test was used to evaluate group differences.  
 
Measurement invariance test 
An invariant measurement model has equal factor loadings, intercepts, factor variances and residual 
variances. Measurement invariance of a scale is a precursor to comparison of group means and 
relationships between the scale and other variables in each group, including income, age, marital 
status and education levels. A least partial measurement invariance is a condition that must be met 
before subsequent comparisons across groups or time can be made. The absence of invariance is 
referred to as non-invariance. The most basic form of invariance is configural or pattern invariance, 
followed by weak, strong and strict factorial invariance, in that order. Below is a short description of 
the four types of measurement invariance and how I applied them in this study. I applied 
measurement invariance testing methods described by Bollen (1989) and Widaman & Reise (1997) 
(Bollen, 1989; Widaman & Reise, 1997). 
 
Configural invariance  
Under configural invariance, I was only interested in testing whether the same indicators measure 
the construct of interest across multiple groups (Bialosiewicz, Murphy, & Berry, 2013). The model 
structure implies that the same item must be an indicator of the latent factor in each group, but the 
magnitude of the factor loadings, intercepts, variances and covariances differ across groups (Sousa, 
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West, Moser, Harris, & Cook, 2012 ). That is, factor loadings, intercepts, variances and covariances 
may be different across groups. It is the baseline model because I assumed the same pattern of fixed 
and free parameters across groups, but no equality constraints are imposed. I can therefore compare 
it with more restrictive models. To estimate this model, the means of adherence and QOL were 
fixed to zero in all groups and factor loadings, intercepts/thresholds, factor and residual variances 
were free to vary across groups.  
 
Weak factorial (factor loading) invariance 
This level of invariance builds upon configural invariance by requiring that in addition to the 
constructs being measured by the same indicators, factor loadings of those indicators must be 
equivalent across multiple groups (Bialosiewicz, Murphy, & Berry, 2013). A factor loading is the 
strength of the linear relation between a latent factor and each of the associated indicators (Bollen, 
1989; Sousa, West, Moser, Harris, & Cook, 2012 ). Under this type of invariance, factor loadings are 
constrained to be equal across groups, but no other equality constraints are imposed. Differences in 
this model imply differences across groups in how the latent variable affects its indicators (Sousa, 
West, Moser, Harris, & Cook, 2012 ). Factor means cannot be compared across groups because of 
differences in the origin of the scale (Sousa, West, Moser, Harris, & Cook, 2012 ). To estimate this 
model, means of adherence and QOL were fixed to zero in all groups, factor loadings were 
constrained to be equal and the rest of the parameters were freely estimated across groups. 
 
Strong factorial (intercept) invariance 
Strong factorial or intercept or scalar invariance justifies across time and between group 
comparisons (Bialosiewicz, Murphy, & Berry, 2013). It builds upon weak factorial or factor loading 
or metric invariance by requiring that the indicator intercepts also be equivalent across multiple 
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groups (Bialosiewicz, Murphy, & Berry, 2013). An intercept is the origin or starting value of the 
adherence or QOL scale that the factor is based on. It can also be defined as the level of adherence 
or QOL when their determinants have no effect on them. In strong factorial invariance, factor 
loadings and intercepts were constrained to be equal across groups. This condition is also called 
“scalar invariance.” This level of invariance is required in order to make valid comparisons of means 
of latent factors across groups (Sousa, West, Moser, Harris, & Cook, 2012 ). The model implies that 
any differences in means of the indicators are attributable to a difference in means of the latent 
variable. Thus, differences in covariances among indicators and in means of indicators are 
attributable to group differences in covariances and means on latent variables (Bollen, 1989). Under 
this invariance model, factor means for adherence and QOL were fixed in one group and free in the 
others, factor loadings and intercepts/thresholds and factor variances were constrained to be equal, 
whereas residual variances were freely estimated. 
 
Strict factorial (residual invariance) invariance 
This is the final level of invariance testing. There are two levels of strict factorial or residual 
invariance (Bialosiewicz, Murphy, & Berry, 2013). The first level is invariance of factor variances, 
which represents overall error in prediction of the latent construct (Bialosiewicz, Murphy, & Berry, 
2013). The second level is invariance of individual indicator variables’ error terms (Bialosiewicz, 
Murphy, & Berry, 2013). Strict invariance testing assesses whether residual errors are equivalent 
across multiple groups. A residual is defined as uniqueness or measurement error associated with 
each measured indicator (Sousa, West, Moser, Harris, & Cook, 2012 ). This type of invariance 
extends strong factorial invariance such that residual variances are also constrained to be equal, in 
addition to factor loadings, intercepts/thresholds and factor variances (Sousa, West, Moser, Harris, 
& Cook, 2012 ). Under this type of invariance, group differences are solely due to group differences 
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in latent variables (Sousa, West, Moser, Harris, & Cook, 2012 ). This type of invariance likely does 
not hold in practice, residual variances would vary from group to group even if all the groups were 
from one population (Bialosiewicz, Murphy, & Berry, 2013). Therefore, I did not estimate models 
for this type of invariance.  
 
Model fit indices and model difference testing 
Measurement invariance was assessed by testing the invariance of measurement parameters across 
the four groups. Parameters included factor loadings, intercepts, factor variances and residual 
variances. To test for invariance, I increased levels of parameter constraints to impose the four types 
of invariance: configural, weak factorial and strong factorial (Bollen, 1989). At each level of 
invariance testing, chi-square statistics were compared with those from the more constrained, nested 
models. For QOL models, which were measured using continuous indicators, I subtracted the chi-
square value from less restrictive configural invariance model from the chi-square value of the more 
restrictive and nested weak invariance model (Bollen, 1989; Widaman & Reise, 1997). Similarly, I 
calculated the difference in degrees of freedom between the two models (Bollen, 1989; Widaman & 
Reise, 1997). The chi-square difference value was compared to the chi-square value in a chi-square 
table using the difference in degrees of freedom between the more restrictive and less restrictive 
models (Bollen, 1989; Widaman & Reise, 1997). A significant chi-square difference value indicated 
that constraining the parameters of the nested model significantly worsened the fit of the model, 
which indicated measurement non-invariance. A nonsignificant chi-square difference indicated that 
constraining the parameters of the nested model did not significantly worsen the fit of the model, 
which indicated measurement invariance of the parameters constrained to be equal in the nested 
model. I did not estimate the next restrictive model if the result was significant, as it suggested that 
the next level of parameter restriction would have significant differences with the previous model. 
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For adherence models, which were measured using binary variables, robust weighted least squares 
(WLSMV) was used to conduct chi-square difference testing using a similar strategy as described 
above for the QOL models.  
I also present model fit indices for specific models such as chi-square values, root mean square error 
of approximation (RMSEA) values, comparative fit indices (CFI)/Tucker-Lewis indices (TLI), 
standardized root mean square residual (SRMR) values for continuous indicators (QOL) and 
weighted root mean square residual (WRMR) values for binary or categorical indicators (adherence). 
A significant chi-square test indicates a poor model fit, but this may also be due to moderate 
discrepancies in normality of data and large sample size (West, Finch, & Curran, 1995). Therefore, 
other model fit indices supplement the chi-square test. The RMSEA is a measure of the estimated 
discrepancy between the population and model implied covariance matrices per degree of freedom 
(Sousa, West, Moser, Harris, & Cook, 2012 ). Values of RMSEA less than 0.05 indicate close model 
fit whereas 0.08 means adequate fit (Sousa, West, Moser, Harris, & Cook, 2012 ). The SRMR and 
WRMR are measures of standardized fitted residuals or the weighted average differences between 
the sample and estimated population variances and covariances and values less than 0.08 for SRMR 
and between 0.95-1.00 for WRMR represent adequate fit (Sousa, West, Moser, Harris, & Cook, 2012 
). The CFI varies from 0 to 1, representing extremely poor and perfect fit respectively and a value of 
0.95 is considered to represent adequate fit (Sousa, West, Moser, Harris, & Cook, 2012 ). 
 
The parent study was approved by the UNC – Chapel Hill IRB, the Ethiopian government, and the 
FHI 360 Ethiopian ethics review committees (Thomas J. , Reynolds, Bevc, & Tsegaye, 2014). I used 
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Microsoft Excel 2013, Stata 1410 and MPlus 7 used for analysis. Summary statistics, factor loadings, 
model fit indices and chi-square tests are reported.  
 
3.3 Results 
The final sample included 225 and 294 participants in Kolfe Keranyo at T1 and T2 respectively. 
Kirkos, the intervention network, had 234 and 293 participants at T1 and T2 respectively. The 
patients were receiving HIV care from 26 and 25 health facilities in Kolfe Keranyo and Kirkos 
respectively at T1 and T2 (see Table 3.1). All participants were female aged between 18 and 45. The 
mean age was 33 (33.06-33.74). Of all participants, 88 percent were receiving antiretroviral therapy 
and one third were living with their spouse. Nearly 25 percent of all participants had never attended 
school, whereas 15 percent had completed at least secondary education.  
 
Factor structure and measurement invariance 
Adherence 
Participant responses to the six indicators/questions on adherence are presented in Table 3.2. Initial 
assessment of correlations between the six indicators of adherence demonstrated that the question 
“did you not take any of your medicine over the last weekend” was weakly and negatively correlated 
(-0.09), with “if at times you feel worse, do you stop taking your medicine” in the T1 intervention 
group, and was, therefore, excluded from the rest of the analysis. All adherence models had good fit 
with similar CFI (0.99). Model fit based on RMSEA was best when all parameters were equated 
across groups (RMSEA=0.04 (95% CI 0.01-0.07)), suggesting that constraining factor loadings, 
intercepts and factor variances improved model fit. All adherence factor indicators, except indicator 
                                                 
10 StataCorp. 2015. Stata Statistical Software: Release 14. College Station, TX: StataCorp LP. 
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5 in the T2 intervention group were statistically significant (p<0.05) across all types of invariance. A 
chi-square difference test between configural and weak factorial invariance models for adherence 
across the four groups was non-significant (chi-square difference = 7.89 (DF=12) p=0.79). Similarly, 
chi-square difference test between weak and strong factorial models was non-significant (chi-square 
difference 17.17 ((DF=24) p=0.84)). Therefore, the best model was strong factorial (see Tables 3.3 – 
3.4). 
 
Quality of life 
Participant responses to the six indicators/questions on adherence are presented in Table 3.5. Model 
fit based on CFI worsened when factor loadings were equated across groups compared to when they 
were unequal (0.95 compared to 0.99). Constraining factor loadings, intercepts and factor variances 
across groups worsened CFI to 0.89. Based on the RMSEA, the model fit worsened when factor 
loadings were equated compared to when they were freely estimated, although other model fit 
indices showed good fit (RMSEA = 0.05 (90% CI 0.02-0.08) p=0.46; compared to 0.09 (90% CI 
0.08-0.11) p=0.00). Constraining all parameters significantly worsened the model based on RMSEA 
0.14 ((90% CI 0.13-0.16) p=0.00). All factor indicators significantly predicted the latent construct, 
QOL (p<0.05). Model fit as measured by chi-square value also worsened from 33.20 ((DF=20) 
p=0.03) to 135.21 ((DF=35) p=0.00) to 293.42 ((DF=50) p=0.00) when one to all parameters were 
constrained across groups. A chi-square difference test between configural and weak factorial 
invariance was significant (chi-square difference = 102.01 (DF=15) p=0.00). A similar test between 
weak factorial and strong factorial invariance was also significant (chi-square difference = 158.21 
(DF=15) p=0.00) (see Tables 3.6 – 3.9).  
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3.4 Discussion 
The study explored the underlying structures of adherence using five-indicator SMAQ and quality of 
life using six-indicator WHOQOL HIV BREF using multiple group confirmatory factor analysis for 
a large sample of HIV-positive Ethiopian women. Adherence indicators demonstrated equivalent 
relationships to the latent factor across four groups: T1 control, T1 intervention, T2 control and T2 
intervention. A similar pattern of invariance was observed when evaluating indicator intercepts, 
indicating that the groups were similar. In addition, factor variances were equivalent across groups. 
Latent means were also equivalent across groups. Thus, strong factorial or scalar measurement 
invariance was found across the four independent study groups, suggesting that indicators were 
being interpreted in an equivalent manner across groups. This finding suggests that the adherence 
scale performs equally across samples. Researchers should be fairly confident that SMAQ 
operationalizes group-specific differences in an invariant manner across groups and time points. 
Therefore, SMAQ can be used to compare and interpret adherence scores across groups in different 
treatment sites and at different time points. In addition, this finding suggests that data collected 
using this instrument from different groups and time can be analyzed together, as if they were from 
one group.  
 
As opposed to the six-indicator SMAQ, I presented results from five indicators of adherence. 
Knobel et al. (2002) validated the use of the six-indicator SMAQ among HIV patients in Spain, in a 
study that found 72 percent sensitivity and 91 percent specificity (Knobel, et al., 2002). The authors 
concluded that SMAQ was an adequate instrument for assessment of adherence among HIV-
infected patients in most settings (Knobel, et al., 2002). Other studies have also used SMAQ to 
assess adherence among HIV-infected patients and other diseases (Pedrol, et al., 2012) (Langebeek, 
et al., 2010; Pedrol, et al., 2012; Dagli-Hernandez, Lucchetta, de Nadai, Galduróz, & Mastroianni, 
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2016; Anglada-Martínez, et al., 2016), among others. However, these studies were limited to settings 
outside of Africa. All these studies used the six-indicator instrument. Due to the nature of their 
work, they did not assess how the instrument measured the construct of adherence. Further, I did 
not find any work that had assessed this important issue in the literature. I suspect that the double-
negative nature of the indicator in question may have confused the respondents, after translation 
from English to Amharic. More studies in African or similar settings are required to further assess 
the invariance of the six-indicator instrument. Future studies should include all the six SMAQ 
questions in their assessment of measurement invariance for medication adherence. Further, the 
implication for this study is the need to assess measurement invariance of SMAQ across age groups 
and gender. These results reflect experiences of Ethiopian women, but gender and culture may have 
differential effects on adherence. Thus, future studies should examine measurement invariance of 
SMAQ across different cultures, races, and socioeconomic status. 
 
Non-significant chi-square difference found in adherence measurement models suggests that 
equating factor loadings, intercepts and factor variances across models did not worsen model fit. 
This finding suggests that the four groups can be analyzed as one group and that the scale used 
consistently measured the same construct across groups. This was not true for the QOL 
measurement models, suggesting that equating all parameters across the models had no effect on 
model fit indices for adherence. 
 
The QOL scale demonstrated pattern or configural invariance, with indicators showing varying 
levels of factor loadings and intercepts to the latent factor. These observed differences may be 
sample-specific and may suggest real differences in levels of QOL. This finding suggests that factor 
indicators used to assess QOL were valid for the latent construct across groups, indicating that 
35 
 
group differences in variances, covariances and means may be attributable to real group differences 
in factor loadings, intercepts, factor variances and residual variances. Such findings may be due to 
real differences in determinants of QOL. The implication of this finding is that the four study 
groups cannot be analyzed as one group, since the findings suggest that despite the presence of 
similar indicators and common factor across groups and time, there were differences in factor 
loadings, intercepts and variances. Levels of QOL between groups can be compared because 
configural invariance, the least form of invariance that warrants valid between and across group 
comparisons, was found in the data.  
 
Configural invariance was found when measurement invariance tests were conducted for QOL 
measures. Overall model fit indices were very good for both measurement models across groups, 
(CFI >0.95). Causes of measurement noninvariance in QOL measurement models are difficult to 
identify, but this may be due to actual real population heterogeneity associated with factors that 
determine QOL in this population, for example, availability of ART and other HIT treatment 
support services. The failed invariance could also be due to differences in interpretations and 
responses to the indicators, meaningful change between the two time points, or random chance. 
Answering this question requires additional research to help adjudicate.   
 
Tesfaye and colleagues (2016) found low internal consistency of the spirituality domain of 
WHOQOL-BREF compared to the other five domains in a study they conducted they among HIV-
positive people in Ethiopia (Tesfaye, et al., 2016). They also reported that the internal consistency of 
five of the six domains of the instrument ranged from acceptable to very good (Tesfaye, et al., 2016). 
Further, an international validation study of the WHOQOL BREF also found suboptimal internal 
consistency in the spirituality domain (O’Connell & Skevington, 2012). Other studies have also 
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suggested fewer domains for the measurement of this construct (Canavarro & Pereira, 2012; Saddki, 
et al., 2009). These findings suggest that although this instrument has been validated across sites, its 
performance varies by population. Thus, my finding of configural measurement invariance is not 
surprising. It may suggest sample differences in characteristics that influence QOL, rather than in 
measurement of the construct.  
 
Finally, this study’s limitations suggest that findings should be interpreted with care. First, because it 
used samples of HIV positive women aged 18 to 45 in Ethiopia, external validity and generalizability 
of the findings to men, other age groups, cultures and races may be limited. Second, it examined 
adherence among women in one part of Ethiopia, thus, it is unclear if these results would be apply 
among HIV positive women of the same age groups from other parts of Ethiopia, where access to 
medication, income, education, marital status and quality of care may be different. 
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3.5 Tables and Figures 
 
Table 3.1: Sample sizes for four study groups 
  
Study site within 
Addis Ababa city 
Total number of 
health facilities and 
organizations 
T1 patient 
interview 
T2 patient 
interview 
Total number 
of participants 
1 Kolfe Keranyo 26 225 294 519 
2 Kirkos 25 234 293 527 
  Total 51 459 587 1046 
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Table 3.2: Responses of patients on ART to the adherence questionnaire 
 
 
  
T1 + T2 (All study groups) 
together 
T1 group T2 group 
 
Question 
 
Responses to 
adherence 
questions (%)   
Responses to adherence questions (%) 
 
Responses to adherence questions (%) 
 
  Observations  All groups 
Observations 
Control (Kolfe 
Keranyo)n=192 
Intervention 
(Kirkos)n=209 Observations 
Control (Kolfe 
Keranyo)n=256 
Intervention 
(Kirkos)n=265 
1 Do you ever forget to take 
your medicine? 
922 Yes 279 (30) 
No 643 (70) 
401 Yes 60 (31) 
No 132 (69) 
Yes 76 (36) 
No 133 (64) 
521 Yes 66 (26) 
No 190 (74) 
Yes 77 (29) 
No 188 (71) 
2 Are you careless at times 
about taking your 
medicine? 
920 Yes 105 (11) 
No 815 (89) 
401 Yes 23 (12) 
No 169 (88) 
Yes 31 (15) 
No 178 (85) 
519 Yes 21 (8) 
No 233 (92) 
Yes 30 (11) 
No 235 (89) 
3 Sometimes if you feel 
worse, do you stop taking 
your medicines? 
920 Yes 78 (8) 
No 842 (92) 
401 Yes 14 (7) 
No 178 (93) 
Yes 19 (9) 
No 190 (91) 
519 Yes 21 (8) 
No 233 (92) 
Yes 24 (9) 
No 241 (91) 
4 Thinking about the last 
week. How often have you 
not taken your medicine? 
922 Never 776 (84) 
1-2 times 115 (12) 
3-5 times 25 (3) 
>5 times 3 (1) 
401 Never 162 (84) 
1-2 times 22 (11) 
3-5 times 6 (3) 
>5 times 2 (1) 
Never 169 (81) 
1-2 times 33 (16) 
3-5 times 7 (3) 
>5 times 0 (0) 
521 Never 222 (87) 
1-2 times 27 (11) 
3-5 times 5 (2) 
>5 times 2 (1) 
Never 223 (84) 
1-2 times 33 (12) 
3-5 times 7 (3) 
>5 times 2 (1) 
5 Did you not take any of 
your medicine over the 
past weekend? 
914 Yes 48 (5) 
No 866 (95) 
401 Yes 9 (5) 
No 178 (95) 
Yes 15 (7) 
No 194 (93) 
513 Yes 13 (5) 
No 235 (95) 
Yes 11 (5) 
No 254 (95) 
6 Over the past 3 months, 
how many days have you 
not taken any medicine at 
all? 
921 ≤ 2 days 843 (92) 
> 2 days 78 (8) 
401 ≤ 2 days 183 (95) 
> 2 days 9 (5) 
≤ 2 days 189 (90) 
> 2 days 20 (10) 
520 ≤ 2 days 227 (89) 
> 2 days 28 (11) 
≤ 2 days 244 (92) 
> 2 days 21 (8) 
N = 926 
56 patients at T1 and 63 patients at T2 were not on ART in this study 
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 Table 3.3: Factor loadings for adherence CFA and types of measurement invariance 
 
  
 
T1 CONTROL GROUP 
Configural  Weak factorial Strong factorial 
 Factor Loadings Factor Loadings Factor Loadings 
Factor Loadings Estimate p-value Estimate p-value Estimate p-value 
Do you ever forget to take your medicine? 1.00 
 
1.00 - 1.00 - 
Are you careless at times about taking your medicine? 0.24 0.05 0.24 0.00 0.24 0.00 
Sometimes if you feel worse, do you stop taking your medicines? 0.45 0.05 0.30 0.00 0.31 0.00 
Thinking about the last week. How often have you not taken your medicine? 0.77 0.05 0.67 0.00 0.67 0.00 
Over the past 3 months, how many days have you not taken any medicine at all? 0.99 0.06 1.00 0.00 1.07 0.00 
 
      T1 INTERVENTION GROUP 
      Factor Loadings Estimate p-value Estimate p-value Estimate p-value 
Do you ever forget to take your medicine? 1.00 
 
1.00 - 1.00 - 
Are you careless at times about taking your medicine? 0.28 0.02 0.24 0.00 0.24 0.00 
Sometimes if you feel worse, do you stop taking your medicines? 0.32 0.02 0.30 0.00 0.31 0.00 
Thinking about the last week. How often have you not taken your medicine? 1.01 0.03 0.67 0.00 0.67 0.00 
Over the past 3 months, how many days have you not taken any medicine at all? 0.93 0.01 1.00 0.00 1.07 0.00 
       T2 CONTROL GROUP 
      Factor Loadings Estimate p-value Estimate p-value Estimate p-value 
Do you ever forget to take your medicine? 1.00 
 
1.00 - 1.00 - 
Are you careless at times about taking your medicine? 0.38 0.03 0.24 0.00 0.24 0.00 
Sometimes if you feel worse, do you stop taking your medicines? 0.38 0.02 0.30 0.00 0.31 0.00 
Thinking about the last week. How often have you not taken your medicine? 0.96 0.02 0.67 0.00 0.67 0.00 
Over the past 3 months, how many days have you not taken any medicine at all? 1.11 0.08 1.00 0.00 1.07 0.00 
       T2 INTERVENTION GROUP 
      Factor Loadings Estimate p-value Estimate p-value Estimate p-value 
Do you ever forget to take your medicine? 1.00 
 
1.00 - 1.00 - 
Are you careless at times about taking your medicine? 0.21 0.03 0.24 0.00 0.24 0.00 
Sometimes if you feel worse, do you stop taking your medicines? 0.30 0.03 0.30 0.00 0.31 0.00 
Thinking about the last week. How often have you not taken your medicine? 0.55 0.02 0.67 0.00 0.67 0.00 
Over the past 3 months, how many days have you not taken any medicine at all? 2.68 0.66 1.00 0.00 1.07 0.00 
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 N=1046 
 
 
 
Table 3.4: Model fit indices and measurement invariance test for adherence questionnaire 
 
 Configural invariance model Weak factorial invariance model Strong invariance model 
Model fit indices Estimate p-value Estimate p-value Estimate p-value 
Chi-square (DF) 55.45 (20) 0.00 52.17 (32) 0.01 62.93 (44) 0.03 
RMSEA (95% CI) 0.09 (0.06-0.12) 0.01 0.05 (0.02-0.08) 0.41 0.04 (0.01-0.07) 0.65 
CFI 0.99 
 
0.99 
 
0.990 
 TLI 0.98 
 
0.99 
 
0.99 
 WRMR 1.55 
 
1.72 
 
1.83 
 Chi-square difference (DF) - 
 
7.89 (12) 0.79 17.17 (24) 0.84 
 
 
 
Table 3.5: Mean scores of QOL domains between groups at T1 and T2 
 
 
Full sample T1 T2 
Quality of life domain Mean (SD) 
Score range 
out of 20  
Control 
Mean (SD) 
Intervention 
Mean (SD) 
Control 
Mean (SD) 
Intervention 
Mean (SD) 
Physical 13.97 (3.58) 4.00 - 20.00 14.04 (3.66) 13.80 (3.58) 13.63 (3.58) 14.41 (3.51) 
Psychological 13.97 (2.94) 4.80 - 20.00 13.47 (2.16) 14.33 (2.67) 13.70 (3.26) 14.34 (3.26) 
Level of independence 12.83 (3.03) 4.00 - 20.00 12.25 (2.53) 12.67 (2.68) 12.61 (3.16) 13.64 (3.36) 
Social relationships 13.21 (3.12) 4.00 - 20.00 12.99 (2.68) 13.35 (3.06) 12.96 (3.49) 13.70 (3.23) 
Environment 10.69 (2.13) 5.00 - 19.00 11.01 (1.80) 11.31 (2.41) 10.22 (2.03) 10.34 (2.06) 
Spirituality / Religion 
/ Personal beliefs 
14.71 (3.21) 5.00 - 20.00 15.28 (3.26) 15.31 (3.35) 13.70 (3.07) 14.78 (2.97) 
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Table 3.6: Factor loadings, means and variances for QOL CFA – part 1 
T1 CONTROL GROUP 
Configural Invariance Weak Factorial Invariance Strong Factorial Invariance 
Factor Loadings Factor Loadings Factor Loadings 
Quality of life domain Estimate p-value Estimate p-value Estimate p-value 
Physical 1.00 - 1.00 - 1.00 - 
Psychological 0.62 0.00 0.94 0.00 0.97 0.00 
Level of independence 0.47 0.00 0.80 0.00 0.82 0.00 
Social relationships 0.65 0.00 0.71 0.00 0.72 0.00 
Environment 0.51 0.00 0.42 0.00 0.42 0.00 
Spirituality/Religion/Personal beliefs 0.82 0.00 0.60 0.00 0.61 0.00 
       Other statistics of quality of life             
Means 0.00 
 
0.00 
 
0.00 
 Variances 5.85   3.74   3.45   
       
T1 INTERVERVENTION GROUP Factor Loadings Factor Loadings Factor Loadings 
Quality of life domain Estimate p-value Estimate p-value Estimate p-value 
Physical 1.00 - 1.00 - 1.00 - 
Psychological 0.79 0.00 0.94 0.00 0.97 0.00 
Level of independence 0.67 0.00 0.80 0.00 0.82 0.00 
Social relationships 0.74 0.00 0.71 0.00 0.72 0.00 
Environment 0.59 0.00 0.42 0.00 0.42 0.00 
Spirituality/Religion/Personal beliefs 0.76 0.00 0.60 0.00 0.61 0.00 
       Other statistics of quality of life             
Means 0.00 
 
0.00 
 
0.55 
 Variances 7.34   6.38   5.95   
       
T2 CONTROL GROUP Factor Loadings Factor Loadings Factor Loadings 
Quality of life domain Estimate p-value Estimate p-value Estimate p-value 
Physical 1.00 - 1.00 - 1.00 - 
Psychological 1.02 0.00 0.94 0.00 0.97 0.00 
Level of independence 0.75 0.00 0.80 0.00 0.82 0.00 
Social relationships 0.69 0.00 0.71 0.00 0.72 0.00 
Environment 0.33 0.00 0.42 0.00 0.42 0.00 
Spirituality/Religion/Personal beliefs 0.49 0.00 0.60 0.00 0.61 0.00 
       Other statistics of quality of life             
Means 0.00 
 
0.00 
 
-0.11 
 Variances 8.04   7.92   7.69   
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Table 3.7: Factor loadings, means and variances for QOL CFA – part 2  
       
T2 INTERVERVENTION GROUP 
Factor Loadings Factor Loadings Factor Loadings 
Quality of life domain Estimate p-value Estimate p-value Estimate p-value 
Physical 1.00 - 1.00 - 1.00 - 
Psychological 1.08 0.00 0.94 0.00 0.97 0.00 
Level of independence 1.01 0.00 0.80 0.00 0.82 0.00 
Social relationships 0.70 0.00 0.71 0.00 0.72 0.00 
Environment 0.40 0.00 0.42 0.00 0.42 0.00 
Spirituality/Religion/Personal beliefs 0.62 0.00 0.60 0.00 0.61 0.00 
       Other statistics of quality of life             
Means 0.00 
 
0.00 
 
0.71 
 Variances 7.34   8.80   8.53   
N=926 
 
Table 3.8: Model fit indices for QOL questionnaire 
Model 
Chi-square (DF); p-
value 
CFI TLI SRMR 
Configural 33.20 (20); p=0.03 0.99 0.98 0.20 
Metric 135.21 (35); p=0.00 0.95 0.92 0.13 
Scalar 293.42 (50); p=0.00 0.89 0.87 0.10 
N=1046 
 
 
Table 3.9: Measurement invariance testing of QOL questionnaire 
Comparisons of models 
Chi-square 
difference 
Difference in 
degrees of 
freedom 
p-value 
  
Weak factorial against configural 102.01 15 
0.00 
   
Strong factorial against configural 260.22 30 
0.00 
   
Strong factorial against weak factorial 158.21 15 0.00 
  
N=1046 
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Figure 3.2: Measurement model for quality of life 
 
 
 
QoL
domain1
ε1
domain2
ε2
domain3
ε3
domain4
ε4
domain5
ε5
domain6
ε6
adherence
q801
1
q802
2
q803
3
q804
4
q806
5
q805
6
Figure 3.1: Measurement model for ART adherence 
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Figure 3.3: Sub cities of Addis Ababa, Ethiopia 
Source: Waste Management Threats to Human Health and Urban Aquatic Habitats – A Case Study 
of Addis Ababa, Ethiopia11 
 
 
 
 
 
 
                                                 
11 Elias Mazhindu, Trynos Gumbo and Tendayi Gondo 
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Census of HIV service 
organizations in two networks 
(Kolfe Keranyo and Kirkos) in 
Addis Ababa, Ethiopia 
Level of organizational 
connectivity (network 
density) in Kolfe Keranyo 
= 0.155, designated as 
control 
T1 interviews with organizational 
representatives and patients 
receiving care in the networks 
Intervention: 
3 workshops held, topics included: 
 patient referral strategies 
 collaboration 
 joint programming 
 organizational service directories 
 sharing organizational contact 
information 
 
Level of organizational 
connectivity (network 
density) in Kirkos = 
0.115, designated as 
intervention 
18 months after T1 interviews, T2 patient and 
organizational interviews about the same topics as 
baseline 
 
No intervention 
 
 
 Network density = 0.067 (reduced) 
 Slight increase in adherence 
 No change in satisfaction 
 No change in QOL 
 
 Network density = 0.183 (increased)  
 Slight increase in adherence 
 Increase in satisfaction 
 No change in QOL 
 
Figure 3.4: Parent study design 
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 AN EXPLORATION OF THE EFFECTS OF ORGANIZATIONAL CHAPTER 4.
NETWORKS AND PATIENT CHARACTERISTICS ON MEDICATION 
ADHERENCE AMONG HIV+ WOMEN IN ETHIOPIA 
 
4.1 Introduction 
In 2013, more than 590,000 Ethiopians over 14 years of age were living with HIV (UNAIDS, 2014). 
HIV treatment is free of charge at public health facilities in Ethiopia through government and donor 
support, but only 50 percent of HIV-positive adults were receiving antiretroviral (ART) therapy in 
2013 (MOH, Ethiopia, 2014). Lack of access to ART compromises adherence, which attenuates 
optimum clinical benefit of ART, and is associated with poor health outcomes and increased 
healthcare costs (WHO, 2001). The WHO reported that access to ART in Ethiopia was 60 percent, 
which is higher than the estimated 50 percent for the rest of Africa (WHO, 2017). According to the 
latest publicly available government statistics, only 70 percent of those who ever started ART were 
currently on treatment, highlighting retention challenges including patient-loss to follow-up, lack of 
adherence to ART regimens, and inadequate capacity to maintain laboratory machines (MOH, 
Ethiopia, 2014). HIV patients need a variety of services, including ART, treatment for opportunistic 
infections, counseling, and nutritional services (WHO, 2017). Because no single facility offers the 
full range of needed services, there is a need for referral of patients and coordination among 
multiple organizations. However, due to inconsistent drug supplies, drug rationing, distrust of 
treatment, lack of HIV service points, and siloed12 and fragmented, HIV care services, many patients 
lack access to HIV treatment and other services that support treatment (Stange, 2009). It is well 
                                                 
12 “Siloed care” depicts lack of collaboration between HIV service and care providers  
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accepted that a system with fragmented and uncoordinated services compromises access and quality 
of care (Berwick, 2011). Optimally, a coordinated group of organizations should serve as a referral 
network to ensure that patients are directed to needed services, and are followed to ensure that they 
receive those services on a timely basis. Access to HIV services is critical to the achievement of the 
second 90 and 95 of the UNAIDS 90-90-90 and 95-95-95 targets of 2020 and 2030, respectively 
(UNAIDS, 2014). 
 
According to the WHO, adherence to treatment is affected by five interrelated factors: (1) socio-
economic factors (2) healthcare team and system factors; (3) condition-related factors; (4) therapy-
related attributes; and (5) patient characteristics (see Figure 4.1) (WHO, 2003). Healthcare team and 
health-system-related factors constitute the healthcare environment in which patients receive care. 
These factors include providers’ schedules, length of appointments, allocation of resources, fee 
structures, communication and information systems, and organizational priorities.  These factors 
have the potential to support or inhibit access to care (WHO, 2003). Thus, factors at multiple levels 
have the potential to affect adherence.  In turn, interventions targeting improved adherence must 
address these determinants of adherence (WHO, 2003). Ignoring these variables can limit the impact 
of the efforts of providers and patients (WHO, 2003).  
 
Several studies have assessed and have found positive associations between adherence and quality of 
life (QOL) (Bader, et al., 2006; Bonjoch, et al., 2005; Chiou, Kuo, Lee, Chen, & P Chuang, 2006; Jia, 
et al., 2004; Luszczynska, Sarkar, & Knoll, 2007; Mannheimer, et al., 2005; Parsons, Braaten, Hall, & 
Robertson, 2006; Patrick & Erikson, 1988; Ruiz-Pérez, et al., 2005; Ruiz-Pérez, et al., 2006) & 
(Sherr, et al., 2007). A systematic review of the literature on adherence and QOL among HIV 
positive patients who were on ART concluded that on average, high adherence rates were associated 
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with increased QOL (Geocze, Mucci, Marco, Nogueira-Martins, & Citero, 2010). Adherence is also 
critical to viral suppression, which is required for the achievement of the third 90 and 95 of the 
UNAIDS 90-90-90 and 95-95-95 targets of 2020 and 2030, respectively (UNAIDS, 2014). 
 
The Ethiopian government, the U.S Global Health Initiative, and The President’s Emergency Plan 
for AIDS Relief have supported the development of referral networks because of their contribution 
to increased access to ART and adherence (PEPFAR, 2014). Recognizing the importance of service 
referral and coordination, the USAID supported a study (the parent study) to strengthen referral 
networks in Ethiopia. Its goals were to address health system factors related to adherence by 
enhancing access to HIV treatment services. Data were collected on patient characteristics, 
adherence and QOL, as well as referral network-and organizational characteristics. This provided the 
opportunity to examine the relationship between organizational and referral network characteristics 
and patient outcomes.  
 
This quasi-experimental study evaluated two non-contiguous HIV treatment referral networks in 
Addis Ababa. Conducted between 2011 and 2012, the study followed the treatment and referral 
experiences of 926 HIV-positive women 18-49 years of age who were receiving ART and other HIV 
care services from two referral network in Addis Ababa (see Figure 4.2). A network strengthening 
intervention was implemented in one of these networks, and was associated with a 55 percent 
increase in organizational ties13 and interactions, also known as referral network density, among 
organizations, and patient satisfaction with care (Thomas J. , Reynolds, Bevc, & Tsegaye, 2014). 
Several other studies found similar associations between improved referral networks and client 
                                                 
13 A tie is linkage or connection between two organizations. It can be a result of referral of patients/samples/experts, 
information exchange, sharing material, joint programs 
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outcomes (Provan & Milward, 2001; Morrissey, Tausig, & Lindsey, 1985; Provan, Veazie, Teufel-
Shone, & Huddleston, 2004; Thomas, Isler, Carter, & Torrone, 2007; McKinney, Morrissey, & 
Kaluzny, 1993). However, while encouraging, previous studies did not distinguish between network 
characteristics and a myriad of other factors or pathways that may have accounted for positive 
patient outcomes. The WHO cited a serious gap in this knowledge base because relatively little 
research has been conducted on the effects of health care team and system-related factors on 
adherence (WHO, 2003).   
 
The objective of this study was to estimate the independent and adjusted effects of patient factors 
and referral networks on patient-reported ART adherence. Through structural equation modeling 
(SEM), this study examined the effect of referral network characteristics as well as patient age, 
income, marital status and education on patient reported ART adherence. I hypothesized that 
patient factors would have significant effects on ART adherence. In addition, I hypothesized that 
the effect of patient-level factors on adherence would be greater than that of the referral network. 
Further, I posited that the intervention network would have higher average adherence than the 
control network at T2. These hypotheses were based on the healthcare utilization model, the 
WHO’s five-dimension theory of treatment adherence, previous publications from the parent study, 
and literature on the associations between adherence and QOL (Andersen R. , 1995; WHO, 2003; 
Thomas J. , Reynolds, Bevc, & Tsegaye, 2014; Thomas J. , Reynolds, Alterescu, Bevc, & Tsegaye, 
2015) 
 
4.2 Methods 
Data used in this study were from a quasi-experimental referral network study conducted by the 
MEASURE Evaluation project. The study enrolled 926 randomly selected HIV positive women 
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who were receiving HIV care from 51 facilities in two non-contiguous sub-cities in Addis Ababa, 
Ethiopia (Thomas J. , Reynolds, Bevc, & Tsegaye, 2014). The two sub-cities were Kirko, designated 
as intervention network and Kolfe Keranyo, the control. Data included organizational 
characteristics, organizational linkages, and patients’ household and individual characteristics. 
Referral network facilities were identified using a snowball sampling technique, resulting in 25 
facilities in Kirkos and 26 in Kolfe Keranyo (see Figure 4.2). To obtain referral network data, T1 and 
T2 interviews were conducted with staff meeting study’s criteria in each health facility about HIV 
services and the nature and types of referrals offered, organizational characteristics, collaborations, 
joint programs and linkages with other facilities.  
 
In addition to interviews with organizational representatives, a cross-section of patients receiving 
care from the sub-cities was interviewed at T1 (March 2011) and a second cross-section was 
interviewed at T2 (December 2012) respectively. Of the 459 patients at T1, 234 were from Kirkos 
and 225 were from Kolfe-Keranyo. Similarly, 293 and 294 patients at T2 were from Kirkos and 
Kolfe-Keranyo respectively. Patients were asked about personal and household-level demographic 
characteristics, HIV care services needed and received, HIV treatment status, QOL, satisfaction with 
care and medication adherence. A referral network strengthening intervention was implemented in 
Kirkos where 21 out of the 25 organizations were represented in at least one of the meetings. The 
intervention was a series of three two-day meetings held two months apart at different times in the 
intervention network after T1 data collection. During the meetings, participants learned about 
strategies for patient referral, collaboration, joint programming, and partnerships. They also learned 
about services offered by other facilities in the network. Service directories, listing contact 
information and services offered, were developed and shared, with each participating facility 
receiving at least one directory. No intervention was implemented in Kolfe Keranyo, - the treatment 
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network designated as a control. Post-intervention interviews for T2 data were conducted 18 
months after T1 using the same questionnaires that were used at T1. Some patients participated in 
both T1 and T2 interviews. Participation in T2 interviews was not conditional on T1 participation; 
the samples were thus independent cross-sections.  
 
Variables and measures 
Adherence was measured as a continuous latent variable. A latent variable is an unmeasured factor, 
an unobserved construct or an indirectly measured factor (Bollen, 2002). Independent or control 
variables included age (years), marital status (binary, 1/0), education (categorical) and a wealth index 
(continuous), which was used as a proxy for income (see below). I used a proxy for income to 
estimate household’s level of economic well-being because 40 percent of respondents had either 
missing values or reported earning no income at all. This variable was thus skewed, not normal (see 
Figure 4.3).  
 
Use of principal components analysis to generate household wealth index 
Due to the limitations of the data on household income, I used principal components analysis to 
derive a linear wealth index from twelve observable household asset indicators. Principal 
components analysis (PCA) is a data reduction process that condenses many observed variables into 
a single measure. In PCA, components are uncorrelated linear combinations of factors (observed 
variables) that maximize the total variance. Other researchers have used this methodology to 
estimate linear wealth indices when income or expenditure data were not available for inclusion in 
statistical analyses (Filmer & Pritchett, 2001). Compared with income, this index better reflected a 
household’s long-term economic status and overall economic well-being.  To generate the wealth 
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index, I included the following household assets, all were measured as categorical and each category 
was converted to binary format:  
 Material used to make the floor, walls and roof of the main house,  
 Main type of toilet,  
 Main source of drinking water,  
 Main source of energy for cooking, and  
 Whether the household owned a car, bicycle, refrigerator, television set, mobile 
phone or a radio.  
The histogram of the first principal component, while not normally distributed, depicts a better 
distribution when compared to that of income (see Figure 4.3). 
 
Measurement of patient medication adherence 
Patients were asked six questions from a standardized scale, known as the Simplified Medication 
Adherence Questionnaire (SMAQ) (See Appendix 2) (CDC, 2013):   
 
1. Do you ever forget to take your medicine?  
2. Are you careless at times about taking your medicine? 
3. Sometimes if you feel worse, do you stop taking your medicines?  
4. Thinking about the last week, how often have you not taken your medicine?  
5. Did you not take any of your medicine over the past weekend? And,  
6. Over the past three months, how many days have you not taken any medicine at 
all?  
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A “yes” response to questions 1, 2, 3 and 5 constituted non-adherence whereas values >0 for 
question 4 and values >2 for question 6 constituted non-adherence. For analysis, the values were 
flipped such that “no,” zero days and ≤2 days constituted adherence for questions 1, 2, 3 and 5, 4 
and 6 respectively. 
 
Measurement model for adherence 
In aim 1, I evaluated the measurement models for QOL and adherence (Agala, et al. (2017). The 
purpose of the measurement model evaluation was to establish the appropriate model fit and factor 
structures so that there would be a sound psychometric basis for comparing individual outcomes 
across time and between communities. In this second aim, I use the measurement model for 
adherence developed in the first aim and include study group, patient’s age, education, income and 
marital status to conduct path analysis.  
 
Path analysis of the medication adherence model 
I expected that individual predisposing and enabling factors would influence patients’ adherence to 
HIV medication. These included age, education, marital status and the wealth index. I hypothesized 
that patients receiving care from the intervention network would be more adherent after the 
intervention, as they were likely to have a higher pool of providers, providing a wider range of 
services that could facilitate adherence, compared to patients receiving care in the control network. I 
included the wealth index because higher index scores reflected higher economic resources. I 
hypothesized that compared to lower levels of economic ability, higher economic resources 
facilitated adherence by increasing patients’ purchasing power, not only for medication but also for 
transportation to the health center, food, counselling, and other products and services. The 
healthcare utilization model classifies income as an individual enabling factor for utilization of health 
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services (Andersen R. , 1995). In addition, a partner could provide social support, which may 
promote adherence. Therefore, patients with social support were more likely to have someone with 
whom they could discuss their treatment and share their experiences and difficulties. A partner may 
also remind them to take their medicine, provide spiritual, emotional, and other support, among 
other benefits. Patients living without a partner were hypothesized to have less support. Stress 
buffering theory suggests that social relationships may provide resources that promote adaptive 
behavioral or neuroendocrine responses to acute or chronic stressors (Cohen, Gottlieb, & 
Underwood, 2001 ). Main effects theory also suggests that social relationships may directly 
encourage or indirectly affect healthy behavior (Thoits, 1983). I theorized that older patients were 
more likely to adhere to their treatment plans compared to younger ones because they were more 
likely to take their health more seriously. Further, I theorized that patients with higher levels of 
education would be more adherent compared to those with lower levels because higher levels of 
education likely to promote health literacy, which may facilitate understanding of benefits of 
adherence and other health information. Other researchers have reported that health literacy 
promotes healthcare utilization (Ishikawa & Yano, 2008; Martin, et al., 2009). Another study by 
Martin and colleagues (2009) also found educational attainment to be the strongest predictor of 
health literacy. Therefore, I allowed age, marital status, education and the wealth index to predict 
adherence. I also allowed these four exogenous variables to covary or vary together with one 
another in a way that may be predictive because they are correlated (see Figure 4.4).  
 
Group comparisons on groups on latent ART adherence 
Structured means analysis and group code analysis have been used to compare groups on latent 
outcomes (Dimitrov, 2006; Aiken, Stein, & Bentler, 1994; Hancock, 1997). Whereas structured 
means analysis requires invariance in both groups under comparison, group code analysis requires 
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that one measurement model holds in both groups (Dimitrov, 2006; Aiken, Stein, & Bentler, 1994; 
Hancock, 1997). I used group code analysis to compare average levels of adherence between the 
four groups at T1 and T2. Comparison study groups were indicated with a dummy variable. I coded 
being in the intervention group as 1 and 0 otherwise. I compared groups at T1 and T2 separately. 
 
Analysis  
I used multiple group analysis technique of structural equation models with diagonally weighted least 
squares (WLSMV) estimation to test study hypotheses. I used WLSMV because adherence indicators 
were ordinal in nature (Li, 2016). WSLMV is specifically designed for analysis of ordinal indicators 
and makes no distributional assumptions about them. However, WLSMV assumes a normal latent 
distribution about the underlying construct, adherence (Li, 2016). Structural equation model 
methodology enabled estimation of direct and indirect effects of exogenous patient factors on 
adherence. I assumed multiple group SEM to evaluate population differences in means and 
measurement in the SEM framework for the four groups under investigation. Because the adherence 
measurement model assessed in the first aim exhibited strong factorial invariance, similar models 
were fitted for each group. In measurement invariance tests conducted under the first aim, 
adherence exhibited intercept or strong factorial invariance, meaning that factor loadings and 
intercepts were equal across time and groups. I reported summary network, organizational and 
patient statistics, unstandardized effect sizes, p-values and model fit indices for the models. Factor 
loadings, intercepts and variances are available but not presented in this paper. Thomas and 
colleagues (2015) have described the methodology for power calculation for the parent study 
elsewhere (Thomas J. , Reynolds, Alterescu, Bevc, & Tsegaye, 2015). The parent study was approved 
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by the UNC – Chapel Hill IRB, the Ethiopian government, and the FHI 360 Ethiopian ethics 
review committees. I used Microsoft Excel 2013, Stata 1414 and MPlus 715 for analysis. 
 
4.3 Results  
Descriptive statistics for patients, organizations and networks 
 
This study included 1046 female patients who were 18-45 years of age and were receiving HIV care 
from 51 HIV service organizations and health facilities in their respective network. The median age 
was 34 years, with a range of 18-45 years of age. Nearly one quarter of all participants had no formal 
education, and only 15 percent had post-primary education. Only one third of the participants lived 
with their sexual partner, of whom two percent were not married to them. Of the 80 percent who 
reported their weekly income, the average income was US$4 (range US$ 0 - 93)16 (see Table 4.1). 
The Ethiopian government owned and operated ten of the 51 service provider organizations, 
whereas non-governmental organizations (NGOs), faith-based organizations (FBOs) or private 
individuals owned and operated the remainder (see Table 4.2). Kirkos had significantly fewer, 
(three), government owned and operated facilities compared to Kolfe, which had seven. There was a 
significant increase in the number of organizations self-identifying as NGOs in Kirkos, from five at 
T1 to 14 at T2. Conversely, Kolfe Keranyo experienced a reduction in the number of NGOs from 
eight at T1 to five at T2. Collectively, organizations in both networks reported significant increases 
in their budgets between T1 and t2. The total budget in the Kirkos network increased US$685,535 
to US$ 1,910,340 and total budget in the Kolfe Keranyo network increased from US$583,171 at T1 
                                                 
14 StataCorp. 2015. Stata Statistical Software: Release 14. College Station, TX: StataCorp LP. 
 
15 Muthen, L. K., & Muthen, B. O. (1998-2010). Mplus user’s guide (6th ed.). Los Angeles, CA: Muthen & Muthen 
 
16 Exchange rate: 2011 US$ 1 = Ethiopian Birr 17.2836 (Source: National Bank of Ethiopia. 
http://www.nbe.gov.et/market/searchdailyexchange.html, accessed Nov 19, 2016) 
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to US$ 5,510,505 at T2. At least five organizations did not report their budget during the two data 
collection periods (range 5-13). Kolfe Keranyo had more staff at both time points compared to 
Kirkos. Kirkos had 1071 and 684 total staff across the network at T1 and T2 respectively, whereas 
Kolfe Keranyo had 1245 and 1213 respectively (see Table 4.2).  
 
Path analysis of adherence 
Bivariate and multivariate comparisons of average adherence levels found no significant differences 
at T1 between intervention and control networks. I conducted similar analyses to establish average 
natural trends of adherence among the participants. My findings showed no significant differences in 
average level of adherence between T1 and T2 in intervention or control networks. There were no 
significant associations between age, education, wealth index or marital status (see Table 4.3 and 
Table 4.4).  
 
Model fit 
The path analysis model for adherence showed good fit (RMSEA = 0.04 (90% CI 0.02-0.05)) and 
CFI of 0.99 (see Table 4.5). 
 
4.4 Discussion  
This study assessed the impact on antiretroviral adherence and patient-related variables of being in 
the intervention network among 926 HIV-positive women who received HIV care from 51 facilities 
in two non-contiguous referral networks in Addis Ababa, Ethiopia. My findings show that the 
intervention had no significant effect on ART adherence in the intervention network compared to 
control at T2. The number of NGOs increased from five to 14 and there were four FBOs in Kirkos, 
the intervention network, compared to a decrease from eight to five NGOs and only one FBO in 
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Kolfe Keranyo, the control network, at T2 compared to T1. In addition, 16 organizations in Kirkos 
compared to seven in Kolfe Keranyo provided home-based care to people living with HIV/AIDS. 
Thomas and colleagues (2014, 2015) also reported increased interaction and referrals between 
facilities in the intervention network compared to control due to the health system strengthening 
intervention there. Increased referrals in the intervention network, together with increased number 
of providers of services may have resulted in increased access to ART and other HIV services in the 
intervention network compared to control at T2. However, according to the WHO’s adherence 
model, adherence requires multi-focal interventions that address systemic, disease-related, treatment-
related and patient determinants in an integrated manner, and increased access to ART alone is 
insufficient to control chronic conditions (WHO, 2001; WHO, 2003). Thus, the increased access to 
medication, patient counseling and education and other HIV services, which were associated with 
higher referral network density there, may have been insufficient to significantly improve adherence. 
In addition, study follow-up time of 18 months may have been too short for the time required for 
adherence to measurably improve.  
 
According to the WHO, adherence to treatment for chronic illnesses has five multi-level 
dimensions: health system/healthcare team, socio-economic, therapy-, patient- and condition-related 
factors (WHO, 2003). It further reported that the ability of clinics and pharmacies to share 
information on patients’ behavior regarding prescription refills has the potential to improve 
adherence (WHO, 2003). My findings, although insignificant, show that the intervention network 
(Kirkos), which had higher network density and a higher rate of information exchange, also reported 
some increased adherence.  
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Our findings also showed that age, education, wealth index and marital status had no effect on 
adherence at T2 in the intervention compared to control. Among those who reported weekly 
income, participants in Kirkos had higher average income than those in Kolfe Keranyo at both time 
points. Similarly, participants from Kirkos had higher average wealth index and education. The 
WHO report indicates that evidence about adherence is biased by the traditional misconception that 
it is a patient-driven problem (WHO, 2003). There is also evidence that the effects of 
sociodemographic factors on adherence differ by setting (WHO, 2003). For example, in the study 
area, situated in a low-income country, patients may have competing priorities such as directing their 
income to meet the needs of other family members (WHO, 2003). A systematic review of studies on 
adherence to ART in Ethiopia concluded that social support was a major predictor of adherence 
(Deyno & Toma, 2014). A qualitative study in Ethiopia also found social support, education and 
counseling, improved health to be some of the facilitators of adherence (Bezabhe, et al., 2014). My 
findings show that marital status, a proxy for social support, did not have a significant effect on 
adherence.  In addition, there is evidence that condition-, therapy- and patient-related factors affect 
adherence (WHO, 2003). Although the network strengthening intervention aimed to improve 
system coordination, the intervention may not have affected a sufficient set of model dimensions. 
As such, its effects on the four dimensions may have been limited and insufficient to significantly 
impact adherence. 
 
Despite Kolfe Keranyo, the control network, having more organizational staff at both time points 
and significantly higher annual budget at T2, ART adherence did not improve over the intervention 
period. This finding suggests that improvements in organizational resources alone may be 
insufficient to provide significant improvements in adherence, as demonstrated by the WHO 
adherence framework (WHO, 2003). It could also suggest that people living in poorer areas need 
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more resources, because they are starting from a less economically advantageous position compared 
to their counterparts from wealthier areas.  
 
Although an intervention that affects the multi-level dimensions of adherence among HIV patients 
may be complex, expensive and time-intensive, my findings suggest that single-dimension 
interventions may be insufficient in improving ART adherence, even though it may have some 
positive effect by increasing access to HIV services. Further studies are necessary to assess whether 
the WHO five-dimensional intervention is feasible, because such an intervention would have the 
potential to improve adherence. My findings suggest that interventions that increase patient referrals 
and access to HIV services are necessary but insufficient to significantly improve adherence. The 
WHO has reported that education in self-management, pharmacy management programs, nurse, 
pharmacist and other non-medical health professional protocols, counselling, behavioral 
interventions, follow-up and reminders increase adherence (WHO, 2001). Further research is needed 
to identify the specific contribution and feasibility of each dimension of WHO’s adherence model in 
low income settings, such Addis Ababa, Ethiopia. This is especially important because it will 
contribute to the achievement of the third 90 and 95 of the UNAIDS FastTrack Initiative.  
 
To further understand the pathways between referral networks and ART adherence, the next aim 
investigates the influences of patient satisfaction and time to ART initiation in the context of these 
findings.  
 
4.5 Study strengths and limitations 
This study used SEM and incorporated a measurement model for adherence to assess the effect of a 
referral network strengthening intervention and patient-level factors on ART adherence. Structural 
equation modeling is an excellent methodology for assessing latent outcomes, such as adherence 
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which was assessed in this study (Bollen, 1989). Structural equation modeling is also a powerful 
methodology for assessing causal relationships. However, the data were from a quasi-experimental 
not a true randomized experimental study. As a result, associations do not do imply causality and 
must be interpreted with care. However, in the context of this study, a quasi-experimental design is 
the best that could have been used; patients could not be randomized into treatment networks and 
organizations with varying HIV treatment access and quality of care issues. That would be unethical. 
Measurement errors affect all variables, but SEM appropriately estimates measurement errors during 
estimation. Network studies are rare in the healthcare context. This study used network concepts to 
improve health outcomes. The intervention was at the health system level, whereas health outcomes 
were measured at the patient-level. This design controlled for potential organizational bias due to 
over-reporting of patient outcomes, if treatment adherence had been assessed at organizational level. 
The intervention shows promise for ART adherence, was rapid and non-complex and is easily 
replicable in any setting.  
 
This study had some limitations. There was no variable linking patients to all of the organizations 
where they received care. As a result, individual-level outcomes could not be assessed by 
organization and clustering of survey respondents by organization was rendered impossible, thus 
recommendations for interventions were limited to patient and network-levels. I resolved this 
limitation by discussing my results in the context of the overall characteristics of the organizations in 
the two networks where the patients received care. Measures of adherence were standardized and 
self-reported. Previous studies have shown that self-reports over-estimate adherence compared to 
more objective measures such as unannounced pill count, CD4 counts and HIV viral loads 
(Tessema, et al., 2010; Biressaw, Abegaz, Abebe, Taye, & Belay, 2013) & (Bezabhe W. , Peterson, 
Bereznicki, Chalmers, & Gee, 2013). Omitted variable bias may have been due to missing measures 
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of comorbidities or individual patient’s own perceived need for care as discussed in the conceptual 
framework of healthcare utilization. 
 
4.6 Tables and Figures 
Table 4.1: Demographic characteristics of participants in the study 
 
Variable 
Kirkos 
Time 1 
Kirkos 
Time 2 
Kolfe Keranyo 
Time 1 
Kolfe 
Keranyo 
Time 2 
Age (SD) 34(6) 34(6) 32(6) 34(5) 
Education 
    1) No school 16% 17% 33% 29% 
2) Adult education 5% 8% 5% 7% 
3) Primary (1-4 grades) 20% 17% 17% 22% 
4) Primary (5-8 grades) 39% 40% 34% 29% 
5) Secondary (9-10 grades) 13% 17% 6% 11% 
6) Preparatory (11-12 grades) 6% 2% 5% 1% 
7) Technical/vocational certificate 0.5% 0 0 0 
8) University degree/associate degree 0.5% 0 0.5% 0 
Marital status     
             1) Married 26% 31% 40% 33% 
             2) Not Married 74% 69% 60% 67% 
Wealth index17(SD) -1.1(1.0) 1.4(1.2) -1.5(0.9) 0.6(1.2) 
Income per week in US$ (SD) 4(7) 6(6) 3(7) 5(6) 
N 210 268 192 256 
Exchange rate: 2011 US$ 1 = Ethiopian Birr 17.2836 (Source: National Bank of Ethiopia. 
http://www.nbe.gov.et/market/searchdailyexchange.html, accessed Nov 19, 2016) 
 
 
                                                 
17 An index (proxy for income) created for each household using principal components analysis from observed 
household assets including: material used to make floor, walls and roof of the main house, main type of toilet, main 
source of drinking water, main source of energy for cooking, and whether the household owned a car, bicycle, 
refrigerator, television set, mobile phone or a radio. 
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Table 4.2: Organizational and network characteristics of HIV service providers 
  
    Type of organization/facility by ownership Annual Budget (US$)   
Total 
Staff 
  
Refer-
ral ties 
  
Netw-
ork 
density Subcity 
Time 
point Govt. NGO FBO Private Total Median Average Total Range 
Kirkos Time 1 3 5 3 13 24 34,107 45,702 685,535 642 - 151,772 1071 69 0.115 
Time 2 3 14 4 3 24 54,454 100,544 1,910,340 1,099 - 289,292 684 101 0.183 
Kolfe 
Keranyo 
Time 1 7 8 0 11 26 28,929 44,859 583,171 2,430 - 119,656 1245 101 0.155 
Time 2 7 5 1 12 25 225,647 344,407 5,510,505 2,893 - 1,967,183 1213 40 0.067 
Total   20 32 8 39 51   8,689,551  4213 311  
 
NGO: Non-governmental organization 
FBO: Faith-based organization 
Exchange rate: 2011 US$ 1 = Ethiopian Birr 17.2836 (Source: National Bank of Ethiopia. http://www.nbe.gov.et/market/searchdailyexchange.html, 
accessed Nov 19, 2016)  
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Table 4.3: Unstandardized estimates of path analysis of adherence 
  Control at T1 Intervention at T1  Control at T2 Intervention T2 
Adherence on: Estimate p-value Estimate p-value Estimate p-value Estimate p-value 
Age 0.02 0.63 0.00 0.88 0.07 0.19 0.01 0.91 
Education -0.14 0.25 -0.16 0.23 -0.18 0.35 -0.30 0.17 
Married 0.07 0.86 0.65 0.10 0.11 0.85 0.65 0.24 
Wealth index -0.11 0.64 -0.21 0.21 0.39 0.14 -0.11 0.67 
*p<0.05; N=926 
 
Table 4.4: Estimates of comparison of adherence between groups 
Comparison without 
control variables 
 
Groups compared 
 
Estimate 
 
p-value 
N=399 T1control compared to T1 intervention 0.42 0.08 
446 T2 control compared to T1 control  0.09 0.72 
474 T2 intervention compared to T1 intervention 0.42 0.17 
521 T2 control  compared  to T2 intervention  0.29 0.42 
Comparison with  
control variables 
N=398 T1control compared to T1 intervention 0.34 0.17 
444 T2 control compared to T1 control  -0.29 0.42 
472 T2 intervention compared to T1 intervention 0.78 0.12 
518 T2 control  compared  to T2 intervention  0.29 0.43 
*p<0.05; N=926 
 
Table 4.5: Model fit indices for full adherence model 
 
 
 
 
 
 
 
 
 
 
 
 
 
N=926 
 
 
 
Model fit Index/measure Adherence 
Chi-Square Test of Model Fit 142.61 
Degrees of Freedom  108 
P-Value 0.01 
RMSEA estimate (90 Percent C.I.) 0.04(0.02 - 0.05) 
Probability RMSEA <= 0.05 0.90 
CFI 0.99 
TLI 0.99 
WRMR value 1.79 
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Figure 4.1: Five dimensions of adherence (WHO, 2003) 
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Figure 4.2: Sub cities of Addis Ababa, Ethiopia 
Source: Waste Management Threats to Human Health and Urban Aquatic Habitats – A Case Study 
of Addis Ababa, Ethiopia18 
  
                                                 
18 Elias Mazhindu, Trynos Gumbo and Tendayi Gondo 
  67 
 
Figure 4.3: Distributions of seven-day income and wealth index 
 
 
Figure 4.4: Path diagram for adherence to antiretroviral therapy 
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 THE MISSING LINK BETWEEN HIV/AIDS REFERRAL NETWORKS CHAPTER 5.
AND POSITIVE HEALTH OUTCOMES AMONG HIV-POSITIVE WOMEN IN 
ETHIOPIA 
 
5.1 Introduction 
It is well understood that individuals undergoing therapy for HIV/AIDS require a range of services 
to support their treatment (WHO, 2017). The providers of these services may constitute a referral 
network, and the strength of the network is dependent upon the level and types of communication 
and coordination among service providers. Higher levels of inter or intra-provider interaction and 
coordination, also referred to as high referral network density, has been shown to improve health 
outcomes because they increase the pool of services from individual providers, which would 
otherwise only offer some but not all of the services needed by patients (Thomas J. , Reynolds, 
Bevc, & Tsegaye, 2014).  
 
Rosenheck et al. (2002), Morrissey et al. (2002), Thomas et al. (2014, 2015), and others have found 
positive associations between high density networks and self-reported health outcomes for 
HIV/AIDS patients and mental health clients (Rosenheck, et al., 2002; Morrissey, et al., 2002; 
Thomas J. , Reynolds, Bevc, & Tsegaye, 2014; Thomas J. , Reynolds, Alterescu, Bevc, & Tsegaye, 
2015). However, little is known about the pathways (i.e., direct and indirect effects) between referral 
networks and patient outcomes, or the mechanisms by which referral networks are associated with 
positive patient outcomes. The study examines these pathways, specifically addressing the direct and 
indirect effects of referral networks on patient outcomes.  
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While previous studies have assessed the structure of referral networks and their overall associations 
with patient outcomes, no previous works have deconstructed the relative effect of direct and 
indirect pathways on patient-reported health outcomes (Thomas J. , Reynolds, Bevc, & Tsegaye, 
2014; Thomas J. , Reynolds, Alterescu, Bevc, & Tsegaye, 2015). For example, patients’ choices of 
health facilities may be affected by the facility or patient characteristics, while the availability and 
nature of health services offered to patients depend on internal characteristics of health facilities in 
the network. A better understanding of these pathways can provide guidance for clinicians and 
managers of health systems as they seek to improve the functioning and impact of health systems.   
 
A direct effect is a relationship between a measured variable and a latent, i.e., unmeasured variable. 
An indirect effect is the relationship between an independent latent variable and a dependent latent 
variable that is mediated by one or more latent variables. The total effect is the sum of direct and 
indirect effects (Weston, 2006). As noted earlier, previous studies have focused on understanding 
the characteristics and structure of organizational networks and their total effects on health 
outcomes. While it is important to acknowledge the beneficial impact of well-coordinated referral 
networks, these analyses do not clarify exactly how the structure of inter-organizational networks 
produce the reported patient outcomes. This study addresses this information gap. I examined direct 
and indirect pathways between HIV/AIDS referral networks, patient-level factors, and patient-
reported health outcomes among HIV-positive women in Ethiopia. These outcomes include delay in 
initiation of antiretroviral therapy (ART) and adherence to ART. Increased understanding of these 
pathways between system characteristics and outcomes can inform the design of targeted patient, 
health facility and network level interventions designed to improve access to and retention of 
patients on HIV treatment. This goal is consistent with and can help facilitate the Ethiopian 
government’s contribution towards attainment of the UNAIDS Fast-Track Initiative goals, 
  70 
popularly known as the 90-90-90 Initiative, which aims to diagnose 90 percent of HIV infections, 
initiate and retain 90 percent of HIV-positive people on ART and reduce new infections and AIDS-
related deaths by 90 percent from 2010-2030 (UNAIDS, 2014; Stover, et al., 2016).  
 
The study’s central thesis is that understanding the direct and indirect effects of the HIV/AIDS 
treatment network is important for comprehensive HIV care policy formulation. The specific aim 
was to identify direct and indirect pathways through which the density of referral networks and 
patient-level factors affect self-reported delay in ART initiation and patient adherence among 926 
HIV+ women in two sub-cities of Addis Ababa, Ethiopia. The two sub-cities were Kolfe Keranyo 
(control) and Kirkos (intervention). The study was conducted between March 2011 (hereinafter 
referred to as Time 1 or “T1”) and December 2012 (hereinafter referred to as Time 2 or “T2”). The 
quasi-experimental study used data collected from patients and nominated organizational or health 
facility representatives at T1 and T2. T2 data were collected 21 months after T1 and 18 months after 
the network improvement intervention in Kirkos. The referral network strengthening intervention 
involved a series of three meetings held at different times in the intervention network after T1 data 
collection in Kirkos. The intervention and data are described in more detail in the Methods section 
of this paper. I hypothesized that:  
i) The intervention would have significant effects on treatment delay and adherence.  
ii) Delay in treatment initiation would have a direct effect on adherence. 
iii) Delay in treatment initiation would mediate the direct and indirect effects of network 
density and patient-level factors on adherence.  
 
5.2 Methods 
Data are from a quasi-experimental referral network study conducted by MEASURE Evaluation 
project. The study enrolled 926 randomly selected HIV positive women who were receiving HIV 
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care from 51 facilities in two non-contiguous sub-cities in Addis Ababa, Ethiopia. These two 
communities are Kirkos and Kolfe Keranyo (see Figure 5.1). The former received an intervention 
aimed at improving coordination among organizations. The data include organizational 
characteristics, organizational linkages, and patients’ household and individual characteristics. 
Referral network facilities were identified using snowball sampling, resulting in 25 facilities in Kirkos 
and 26 in Kolfe Keranyo. To obtain referral network data, T1 and T2 interviews were conducted 
with nominated key informants in each health facility about HIV services and the nature and types 
of referrals offered, organizational characteristics, collaborations, joint programs and linkages with 
other facilities.  
 
In addition to interviews with organizational representatives, a cross-section of patients receiving 
care from the sub-cities was interviewed at T1 (March 2011) and a second cross-section was 
interviewed at T2 (December 2012) respectively. Of the 459 patients at T1, 234 were from Kirkos 
and 225 were from Kolfe-Keranyo. Similarly, 293 and 294 patients at T2 were from Kirkos and 
Kolfe-Keranyo respectively. In the patient interviews, patients were asked about personal and 
household-level demographic characteristics, HIV care services needed and received, HIV treatment 
status, satisfaction with care and medication adherence. A referral network strengthening 
intervention was implemented in Kirkos where 21 of the 25 organizations were represented in at 
least one of the meetings. The intervention consisted of a series of three two-day meetings held two 
months apart at different times in the intervention network after T1 data collection. During the 
meetings, participants learned about strategies for patient referral, collaboration, joint programming, 
and partnerships. They also learned about services offered by other facilities in the network. Service 
directories, listing contact information and services offered, were developed and shared, with each 
participating facility receiving at least one directory. No intervention was implemented in Kolfe 
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Keranyo, the control network. Post-intervention interviews for T2 data were conducted 21 months 
after T1 and 18 months after the intervention using the same questionnaires as T1. Although some 
patients participated in both T1 and T2 interviews, participants in T2 interviews was not conditional 
on T1 participation. Consequently, the samples were thus independent of each other.  
  
This study applies Andersen’s (1995) theory of healthcare utilization, which uses a systems 
perspective to assess the impact of environmental-, organizational- and patient-level factors on 
health services utilization, which in turn affects patient outcomes, as depicted in Figure 5.2 and 
discussed below (Andersen R. , 1995). 
 
Variables and measures 
In addition to adherence, patient’s age, education, marital status and wealth index, delay in ART 
initiation and patient’s satisfaction with HIV care and other treatment support services have been 
included in this aim. Both treatment delay and satisfaction were categorical variables.  
 
Delay in treatment initiation 
All participants were asked how long it had been since they first learned they were HIV-positive and 
if they were currently on ART. Respondents who indicated that they were currently on ART were 
also asked the length of time they had been on therapy. Responses were recorded in weeks, months 
and years. Since I could not tell precisely when a patient was truly first infected with HIV, I assumed 
that the reported date of first HIV-positive test was the date of infection, but I suspect that patients 
were diagnosed with HIV and AIDS concurrently. Literature suggests that roughly 15-43 percent of 
HIV-positive people in low-income countries present for care with advanced stage (Stage 3) disease 
or CD4 count at or below 350 cells per cubic millimeter, and that late diagnosis and delayed ART 
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initiation are very common even in high-income settings (Abaynew, Deribew, & Deribe, 2011; 
WHO, 2015). As of September 2015, the WHO recommends treatment initiation as soon as one 
tests HIV-positive regardless of CD419 count, but initiation within 30 days is considered to be on 
time (WHO, 2015). The latest Ethiopian guidelines, which were published in 2008 require CD4 
count below 200 cells per cubic millimeter for clinical stages 1 and 2 disease, but all patients with 
stage 3 or 4 disease with a CD4 count of 350 cells per cubic millimeter or below are recommended 
for treatment initiation (MOH Ethiopia, 2008). In line with WHO guidelines, the Ethiopian 
guidelines also require clinical assessment where CD4 testing is not available (MOH Ethiopia, 2008). 
It recommends coordination between laboratory and sample transportation to increase access to 
CD4 testing at health centers (MOH Ethiopia, 2008). To generate a measure of delay in treatment 
initiation, I calculated the difference (in days) between the time participants first knew they were 
HIV-positive and first use of ART. Based on WHO’s definition of delay in HIV treatment initiation 
and clinical staging of HIV as described by AIDS.gov20 (see Figure 5.3 and Figure 5.4), treatment 
delay was divided into five categories for my analysis: "1. Less than 31 days", "2. 31-180 days", "3. 
181-365 days", "4. 366-3650 days" and "5. More than 10 years". These categories were used for ease 
of interpretation of results, and were based on clinical stages of HIV, assuming no treatment 
(AIDS.gov, 2014; WHO, 2015). Treatment initiated within the first month of diagnosis was 
considered to be timely (WHO, 2015). 
 
 
                                                 
19 CD4 is a type of lymphocyte. CD4 T lymphocytes (CD4 cells) help coordinate the immune response by stimulating 
other immune cells, such as macrophages, B lymphocytes (B cells), and CD8 T lymphocytes (CD8 cells), to fight 
infection. HIV weakens the immune system by destroying CD4 cells. 
 
20 Source: Stages of HIV infection – how does HIV progress in your body? https://www.aids.gov/hiv-aids-
basics/just-diagnosed-with-hiv-aids/hiv-in-your-body/stages-of-hiv/. Accessed October 20, 2016. 
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Use of treatment delay as a mediator 
In this paper, I introduced treatment delay in the model as a mediating variable between individual 
patient-related factors and adherence. Treatment delay is considered a mediator if variations in the 
exogenous variables (i.e., age, education, marital status and wealth index) significantly account for 
variations in treatment delay, variations in treatment delay significantly account for variations in 
adherence, and when the foregoing two associations are controlled, a previously significant 
relationship is no longer significant (see Figure 5.5) (Baron & Kenny, 1986). I ran three regressions 
to test for treatment delay as a mediator. First, I regressed treatment delay on the exogenous 
variables. Second, I regressed adherence on the exogenous variables. Finally, I regressed adherence 
on treatment delay and the exogenous variables together. For treatment delay to be considered a 
mediator in this model three conditions must be met. The exogenous variables must affect the 
mediator in the first regression, the exogenous variables must affect adherence in the second 
regression, and finally, treatment delay must affect adherence in the third regression. If all these 
conditions hold, the effect of the exogenous variables on adherence must be less in the third than in 
the second regression. Whereas full or perfect mediation occurs when the exogenous variables have 
no effect on adherence, partial mediation occurs when the exogenous variables have some but less 
effect on adherence than treatment delay in the third regression (see Figure 5.5) (Baron & Kenny, 
1986). 
 
Satisfaction with HIV/AIDS Care 
Patient satisfaction with HIV care is an important indicator for QOL and health outcomes among 
HIV-positive people. Literature suggests that patients who are satisfied with their HIV care are more 
likely to be retained in care and retention in care is one of the goals of the UNAIDS Fast-Track 90-
90-90 Initiative (Roberts, 2002; Chimbindi, Bärnighausen, & Newell, 2014; Dang, Westbrook, Black, 
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Barradas, & Giordano, 2013; UNAIDS, 2014; Stover, et al., 2016). I hypothesized that adherence 
and satisfaction with HIV care have a concomitant association. Thus, patients with higher adherence 
scores were more likely to have better health outcomes, including less disease severity, which is likely 
to lead to higher satisfaction. I also hypothesized that treatment delay indirectly affects satisfaction, 
through adherence. Thus, patients with higher adherence scores were more likely to be more 
satisfied with HIV care. Moreover, patients with higher satisfaction scores are more likely to follow 
providers’ instructions and therefore report higher satisfaction. However, I did not test the 
foregoing association due to lack of an appropriate instrumental variable. More adherent patients are 
more likely to have improved functional status, which may improve their satisfaction. 
Patients responded to four questions about satisfaction:  
1. Do you feel that your health needs are being met? Would you say that: 1. All your health 
needs are being met; 2. Most are being met; 3. Some are being met, or 4. Very few or none 
are being met? 
2. Overall, how satisfied have you been with the care services you receive for your HIV 
disease? Would you say: 1. Very satisfied; 2. Somewhat satisfied; 3. Somewhat unsatisfied; or 
4. Unsatisfied? 
3. Overall, how satisfied have you been with family planning services you receive? Would you 
say: 1. Very satisfied; 2. Somewhat satisfied; 3. Somewhat unsatisfied; or 4. Unsatisfied? 
4. Which HIV or FP services are you particularly very satisfied/unsatisfied with? Responses for 
this question were free-entry and open-ended format. 
 
I recoded the values from 1-4 to 4-1 to make the scale intuitive such that the highest satisfaction 
level was coded with the highest number in the scale. These questions were asked of all participants 
and may have been influenced by satisfaction levels of various types of health services needed and 
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received, for example family planning services, not just HIV/AIDS care and support services. I 
could not disentangle the components of the responses for the three questions, which were 
nonspecific to HIV/AIDS care and support. Therefore, I only used the second question on the list 
above to measure satisfaction. Methodologies for measurement of adherence and QOL have been 
described in the second aim of this dissertation research series. 
 
Comparison of groups on latent adherence 
In my first paper, I found measurement invariance in adherence but not in QOL, and concluded 
that meaningful comparisons could be made for adherence but not QOL. Structured means analysis 
and group code analysis have been used to compare groups on latent outcomes (Dimitrov, 2006; 
Aiken, Stein, & Bentler, 1994; Hancock, 1997). I used the group code analysis method to compare 
levels of adherence between groups (Dimitrov, 2006; Aiken, Stein, & Bentler, 1994; Hancock, 1997). 
This methodology uses data from both groups in a single SEM model and indicating the groups with 
a dummy variable. I coded being in the intervention group as 1 and 0 otherwise. 
 
Measurement and path analysis models for treatment delay and adherence 
In aim 1, I evaluated the measurement models for QOL and adherence. I integrated these models 
into path analyses in aim 2. The purpose of the measurement model assessment was to establish the 
appropriate model fit and factor structures to facilitate valid comparisons between levels of latent 
outcomes. The purpose of the second aim was to assess the effect of the intervention on adherence 
and the relationships between exogenous variables (age, marital status, education and wealth index), 
the latent construct (adherence) and the factor indicators. I also compared the level of adherence 
across groups and time points. I made these comparisons to assess equivalence in the levels of the 
latent outcome at baseline, effects of the 18-month time difference between baseline and follow-up, 
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and the effect of the intervention at follow-up for both experimental groups. In this aim, I 
introduced treatment delay as a mediating variable between adherence and exogenous variables, and 
added satisfaction as an exogenous variable in the model. The purpose of this analysis is to assess 
the effect of treatment delay and satisfaction on adherence as well as to assess whether treatment 
delay fully or partially mediates the relationship between adherence and the exogenous variables. In 
this model, I hypothesized that treatment delay is an intermediate outcome that is influenced by 
individual patient-related factors and being in the intervention network. I also hypothesized that it 
influences adherence. The contribution of this analysis is the potential use of the results to guide 
interventions. According to the healthcare utilization model, patient-level factors are more difficult 
to modify through an intervention. On the contrary, treatment delay can be influenced by 
interventions targeting health systems and health care teams, such as promotion of early HIV 
testing, widespread availability of HIV testing services, provision of mobile HIV testing centers, 
availability of ARVs, training more healthcare personnel, improved quality of care, among other 
strategies. In addition, I added satisfaction with HIV/AIDS care as an exogenous variable, instead of 
a latent outcome in the model because it was measured using only one question. I assumed that the 
single question measured satisfaction with HIV/AIDS care and support services fully. I 
hypothesized that patients who were satisfied with their care would be more adherent than patients 
who were less satisfied. Several studies have also shown a positive association between satisfaction 
with care and medication adherence (Roberts, 2002; Oetzel, et al., 2015; Dang, Westbrook, Black, 
Barradas, & Giordano, 2013). I therefore allowed satisfaction and treatment delay to predict 
adherence (see Figure 5.1).  
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Analysis 
In the first aim, I used multiple group analysis technique of structural equation models with 
maximum likelihood (ML) and diagonally weighted least squares (WLSMV) estimation to develop 
measurement models for adherence and QOL. In the second aim, I integrated the measurement 
models, which were developed in the first aim with path analyses for the exogenous patient 
characteristics and the latent constructs. To develop the model for the third aim, I added satisfaction 
and delay in ART initiation. Whereas satisfaction was included as an exogenous variable, I 
introduced delay in ART initiation as an intermediate outcome and a mediating variable in the 
model. Therefore, I assessed direct and indirect effects of being in the intervention network at T2, 
age, education, marital status, wealth index and satisfaction on delay in ART initiation and 
adherence. I used multiple group SEM to evaluate population differences in means, measurement 
and structural relationships in the SEM framework for the four groups under investigation. I used 
maximum likelihood ordinal logistic regression in the SEM framework to assess the levels of delay in 
ART across the four groups and to assess the effect of the independent variables on levels of delay 
in ART initiation. I used maximum likelihood estimation for adherence as a latent continuous 
outcome. Ordinal logistic regression coefficients that describe the relationship between the lowest 
category of treatment delay versus all higher categories are the same as those that describe the 
relationship between the next lowest category all higher categories, also known as the proportional 
odds assumption or parallel regression assumption. Because of this assumption, there is only one set 
of coefficients that describes the relationship between the predictors and treatment delay.  
 
I report summary network, organizational and patient statistics, unstandardized effect sizes, p-values, 
odds ratios and model fit indices for the models. Further, I decompose and present statistically 
significant total, direct and indirect effects. Factor loadings, intercepts and variances were presented 
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in paper one of this dissertation research series. Thomas and colleagues (2015) have described the 
methodology for power calculation for the parent study elsewhere (Thomas J. , Reynolds, Alterescu, 
Bevc, & Tsegaye, 2015). The parent study was approved by the UNC – Chapel Hill IRB, the 
Ethiopian government, and the FHI 360 Ethiopian ethics review committees. I used Microsoft 
Excel 2013, Stata 14 and MPlus 7 for analysis (StataCorp, 2015; Muthen & Muthen, 1998-2010).  
 
5.3 Results 
Descriptive statistics of patients, organizations and networks 
This study consisted of 926 female patients who were 18-45 years of age and were receiving HIV 
care from 51 HIV service organizations and health facilities in both networks. The median age was 
34 (range 18-45). Only one third of the participants lived with their sexual partner, of whom two 
percent were not married to them. Nearly one quarter of all participants had no formal education, 
and only 15 percent had post-primary education. Of the 80 percent who reported their weekly 
income, the average income was US$4 (range US$ 0 - 72)21 (see Table 5.1). Table 5.2 shows a 
summary of patient responses to indicators of adherence. The Ethiopian government owned and 
operated ten out of the 51 service providers, whereas non-governmental organizations (NGOs), 
faith-based organizations (FBOs) or private individuals owned and operated the remainder. Kirkos 
had significantly fewer, (three), government owned and operated facilities compared to Kolfe, which 
had seven. There was a significant increase in the number of organizations self-identifying as NGOs 
in Kirkos from five at baseline to 14 at follow-up. Conversely, Kolfe Keranyo experienced a 
reduction in the number of NGOs from eight at baseline to five at follow-up. Organizations in both 
networks reported significant increases in their budgets at follow-up compared to baseline, Kirkos 
had a total budget of US$685,535 and US$ 1,910,340 whereas Kolfe Keranyo had US$583,171 and 
                                                 
21 Exchange rate: 2011 US$ 1 = Ethiopian Birr 17.2836 (Source: National Bank of Ethiopia. 
http://www.nbe.gov.et/market/searchdailyexchange.html, accessed Nov 19, 2016) 
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US$ 5,510,505 at baseline and follow-up respectively. At least five organizations did not report their 
budget during the two data collection periods (range 5-13). Kolfe Keranyo had more staff at both 
time points compared to Kirkos. Kirkos had 1071 and 684 total staff across the network at baseline 
and follow-up respectively, whereas Kolfe Keranyo had 1245 and 1213 respectively. As reported by 
Thomas et al (2014, 2015), Kirkos had 69 and 101 referral ties and network densities of 0.115 and 
0.183 at T1 and T2 respectively (Thomas J. , Reynolds, Bevc, & Tsegaye, 2014; Thomas J. , 
Reynolds, Alterescu, Bevc, & Tsegaye, 2015). Similarly, Kolfe-Keranyo had 101 and 40 referral ties 
and network densities of 0.155 and 0.067 at T1 and T2 respectively (see Table 5.3).  
 
Full model results for treatment delay and adherence 
All indicators of adherence significantly predicted the latent outcome (p<0.05). The odds of higher 
treatment delay versus lower for patients who were married and were in the control network at T2 
were 1.56 times higher than for those who were not (p<0.05). Satisfaction with care significantly 
predicted adherence in both groups at T2, with a total effect of 0.6 and one-point increase in the 
control and intervention groups respectively (p<0.05). Adherence and treatment delay had an 
inverse association with one another in the intervention group at T2. A unit increase in treatment 
delay was associated with 0.7 points reduction in adherence score in the intervention group at T2 
(p<0.05). Whereas all hypothesized total and direct effects reported from the full model were 
statistically significant, all associated indirect effects were not (p<0.05) (see Tables 5.4 and 5.5). 
Being in the intervention compared to control group at T2 was associated with significantly lower 
odds of treatment delay. The odds of higher treatment delay versus lower for patients in the 
intervention network at T2 were 27 percent lower than those in the control network (p<0.05) (see 
Table 5.5).  
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After finding a significant decrease in treatment delay in the intervention network at T2, I conducted 
sensitivity analysis using the difference in differences technique, which demonstrated that on average 
a patient in the intervention network was initiated on ART 70 days earlier compared to their 
counterpart in the control at T2 (687 days in control versus 617 days in the intervention). However, 
the intervention network had quicker ART initiation even at T1 than control. Taking the difference 
at T1 into account there was a net average effect of 15 days quicker ART initiation in the 
intervention network compared to control (median number of days of delay was 225 in the 
intervention network compared to 365 in the control at T2 (see Table 5.6). However, my findings 
show that the intervention did not have a significant effect on medication adherence. Tests for 
treatment delay as a mediator were indeterminate. Only one condition for perfect mediation was 
met. A decrease in treatment delay significantly and positively predicted adherence (p<0.05).  
 
Model fit 
The full model for treatment delay, adherence and QOL showed good fit (RMSEA = 0.04 (90% CI 
0.03-0.05)), CFI of 0.97 and TLI of 0.96 (see Table 5.7). 
 
5.4 Discussion  
My findings show that the intervention had significant positive effects on (decreased) treatment 
delay among participants in the intervention network at T2. Thomas and colleagues (2015) reported 
increased interactions and referral of patients between service providers in the intervention network 
compared to control at T2 (Thomas J. , Reynolds, Alterescu, Bevc, & Tsegaye, 2015). Increased 
referrals in this network led to an increase in the number of services available to patients, which may 
have increased access to HIV/AIDS services, leading to quicker ART initiation by providers in the 
intervention network. A net reduction in average treatment delay of 15 days, which was observed in 
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the intervention network at T2, is significant, but modest. Evidence suggests a 15-day improvement 
in ART initiation has some clinical benefit for patients with more advanced HIV infection (stage 3 
or 4) who are likely to develop life-threatening opportunistic infections (WHO, 2015). In addition, 
there is some public health benefit for those with higher viral loads and who are sexually active 
(WHO, 2015). Cohen and colleagues (2011) reported the benefits of early ART initiation in detail 
(Cohen, et al., 2011). My findings demonstrate that the intervention, although rapid, simple and 
affordable, is a feasible way to improve rate of ART access.  
 
Further, I found that delay in ART initiation was inversely related to adherence among participants 
in the intervention group, after the intervention. This finding suggests that patients with longer 
treatment delay periods had lower adherence scores. It suggests that the very same network-level 
factors that lead to delay in treatment initiation may have a similarly negative effect on adherence 
among patients. This association affirms the finding that the intervention enhanced the speed of 
ART initiation in the intervention group compared to control at T2. However, the enhanced speed 
of treatment initiation was not sufficient to significantly improve adherence. The WHO describes 
medication adherence as a multi-factor and multi-level outcome, which suggests that an intervention 
at only one level may not significantly improve adherence (WHO, 2003). While the intervention was 
a system-level activity that reorganized and created a more coordinated care at the level of health 
facilities within the intervention network, it did not have components targeting condition-related, 
patient-related, therapy-related or socio-economic factors. 
 
My findings also showed that an increase in satisfaction with care increased adherence. Roberts 
found patient satisfaction with care to be positively associated with HIV treatment adherence and 
concluded that strengthening relationships between patients and care providers should be a priority 
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(Roberts, 2002). Other studies have also found that patient satisfaction is an important factor for 
uptake, adherence and retention in treatment and that unsatisfied patients are likely to discontinue 
seeking care or to change providers (Roberts, 2002; Chimbindi, Bärnighausen, & Newell, 2014; 
Dang, Westbrook, Black, Barradas, & Giordano, 2013). 
 
Counter to my hypothesis, which was based on social support promoting early HIV-testing and 
treatment initiation among married patients, my findings showed that married patients in Kolfe 
Keranyo at T2 were initiated on ART later than unmarried patients in the same network. It is 
possible that married patients were less likely to seek care earlier due to stigma and discrimination 
associated with being HIV-positive or fear of divorce or separation from spouses. For similar 
reasons, they may have been less likely to disclose their HIV status to their spouses, even if they had 
tested and knew they were HIV-positive. This finding may also be due to Kolfe Keranyo being more 
rural compared to Kirkos. People in more rural settings are more likely to live with families than 
those in more urban ones. Anonymity in more urbanized settings may be associated with less 
perceived stigma and promote early testing and treatment seeking behavior. Abaynew and colleagues 
(2011) found that people who: lived with their families, had lived more than two years with a steady 
partner, had not disclosed their HIV status and perceived HIV stigma to be high, presented late for 
HIV treatment (Abaynew, Deribew, & Deribe, 2011).  
 
The model assessed in this study provides a linkage between patient-reported outcomes and 
exogenous patient characteristics in a referral network framework; has not been previously done. 
Previous studies have assessed global network-level effects on health outcomes (Provan & Milward, 
2001; Morrissey, Tausig, & Lindsey, 1985; Provan, Veazie, Teufel-Shone, & Huddleston, 2004; 
McKinney, Morrissey, & Kaluzny, 1993; Thomas, Isler, Carter, & Torrone, 2007). Other studies 
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have assessed relationships between two or three of these outcomes, yet only some of the 
relationships which were assessed in this study were previously evaluated (Oetzel, et al., 2015). In 
many instances, studies did not include the measurement models of the relevant constructs, making 
valid comparisons difficult (Oetzel, et al., 2015).  
 
Further, my findings show that treatment delay was not a valid mediator for associations between 
patients’ age, education, marital status and wealth. This finding may be because the health system-
level intervention did not affect individual patient-factors in any way during the period of the study, 
and may be analogous to the nonsignificant finding on associations between the patient-level factors 
and adherence. However, treatment delay may still be a valid mediating variable in practice. This is 
potentially because it varies by individual patient, may be influenced by the patient’s perceived need 
for treatment, had a significant association with adherence in the full model after the intervention, 
and it is modifiable through patient-, organizational- or system-level interventions.  
 
The UNAIDS FastTrack Initiative is a framework that describes a roadmap for actions required to 
achieve the 90-90-90 and 95-95-95 treatment cascades by 2020 and 2030 respectively (UNAIDS, 
2014; Stover, et al., 2016). It aims to diagnose 90 percent of HIV-infected people, initiate and retain 
90 percent of those diagnosed on treatment and achieve viral suppression among 90 percent of 
those initiated and retained on treatment by 2020. The 95-95-95 targets for 2030 are similar to those 
of 90-90-90. It is a scale-up initiative for ART that calls for rapid interventions: to increase value for 
money and efficient use of limited funds and resources, that are affordable to local governments, 
and that lead to increased community-based service delivery that brings services closer to the people 
who need them to improve service uptake (UNAIDS, 2014; Stover, et al., 2016). My findings suggest 
that the rapid, affordable and noncomplex referral network strengthening intervention, which was 
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assessed in this study, may be one such initiative. It was associated with an enhanced speed of ART 
initiation, which significantly and positively predicted adherence. Adherence to ART is required for 
viral suppression. According to the UNAIDS, achievement of the third target requires sustained use 
of HIV treatment and ongoing virologic monitoring to verify treatment success and to intervene to 
support adherence and re-engage those who drop out of treatment (UNAIDS, 2014). This 
intervention has promise in contributing to the FastTrack Initiative because it is easily replicable in 
low-resource settings, such as the sub-Saharan Africa where the burden of HIV/AIDS is highest.  
 
This study suggests that interventions that enhance referral networks can reduce treatment delay and 
contribute to increasing adherence to ART. It also suggests that interventions that target adherence 
should be multi-level. Finally, it suggests that interventions that enhance patient satisfaction, 
treatment delay and adherence are critical if the UNAIDS Fast-Track goals are to be achieved.  
 
5.5 Study strengths and limitations 
Measures of adherence were standardized and self-reported and were thus subject to patient 
interpretation, response and over-reporting. Previous studies have shown that self-reports over-
estimate adherence compared to more objective measures such as unannounced pill count. The 
absence of clinical variables such as CD4 cell counts and HIV viral load limits the objectivity of 
adherence measurement (Biressaw, Abegaz, Abebe, Taye, & Belay, 2013; Bezabhe W. , Peterson, 
Bereznicki, Chalmers, & Gee, 2013; Tessema, et al., 2010). The measure for satisfaction was also 
subjective. However, self-reports were the most appropriate method, because the patient’s 
perception was central to the measures. The data did not contain a variable for the patient’s main 
provider, which would have made it possible to cluster my results and potentially provide better 
feedback to the organizations that participated in the study. 
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By nature, referral networks are dynamic. Whereas studying network characteristics at given time-
points is one way to learn about networks and how they operate, the dynamic nature of networks 
makes point-in-time studies have potentially less effective interventions. There may be better 
potential for more relevant interventions with studies that recognize and integrate the dynamic 
characteristics of organizational networks. Such studies may lead to interventions which are more in 
line with the dynamic nature of networks. Therefore, this study depicts the shape and nature of the 
two networks at a point in time and space. However, assuming there is not much change on average 
network characteristics under investigation, interventions derived from the results of such a study 
may be useful in improving health outcomes for patients receiving care from health facilities in the 
network. This study also has some methodological limitations. Threats to internal validity associated 
with cross-sectional design and nonequivalent groups due to local history or context and selection 
maturation also limited inferences about causal effects. Structural equation modeling is a powerful 
methodology for causal relationships. However, the data used for this dissertation are from a quasi-
experimental not experimental study thus associations do not do imply causality and were 
interpreted with caution. However, in the context where these data were collected, quasi-
experimental design is the best that could have been used, given the limited resources that could not 
support inclusion of more organizations and their randomization for intervention. Also, patients 
could not be randomized into treatment networks with varying HIV treatment access and quality 
issues. That would be unethical. In addition, network interventions with a comparison network are 
rare. The presence of a comparison network in this study is a significant strength.  
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5.6 Tables and Figures  
Table 5.1: Demographic characteristics of participants in the study 
Variable 
Kirkos 
Time 1 
Kirkos 
Time 2 
Kolfe Keranyo 
Time 1 
Kolfe 
Keranyo 
Time 2 
Age (SD) 34(6) 34(6) 32(6) 34(5) 
Education 
    1) No school 16% 17% 33% 29% 
2) Adult education 5% 8% 5% 7% 
3) Primary (1-4 grades) 20% 17% 17% 22% 
4) Primary (5-8 grades) 39% 40% 34% 29% 
5) Secondary (9-10 grades) 13% 17% 6% 11% 
6) Preparatory (11-12 grades) 6% 2% 5% 1% 
7) Technical/vocational certificate 0.5% 0 0 0 
8) University degree/associate degree 0.5% 0 0.5% 0 
Marital status     
             1) Married 26% 31% 40% 33% 
             2) Not Married 74% 69% 60% 67% 
Wealth index22(SD) -1.1(1.0) 1.4(1.2) -1.5(0.9) 0.6(1.2) 
Income per week in US$ (SD) 4(7) 6(6) 3(7) 5(6) 
Treatment delay     
1) <31 days 44% 38% 36% 30% 
2) 31-180 days      4% 8% 6% 11% 
3) 181-365 days 20% 16% 19% 9% 
4) 366-3650 days 31% 35% 38% 43% 
5) > 10 years 0.5% 3% 0.5% 7% 
Satisfaction with HIV/AIDS care and support     
4) Very satisfied 65% 49% 59% 52% 
3) Somewhat satisfied 26% 44% 23% 42% 
2) Somewhat unsatisfied 6% 4% 15% 4% 
1) Unsatisfied  3% 3% 3% 2% 
N 210 268 192 256 
 
Exchange rate: 2011 US$ 1 = Ethiopian Birr 17.2836 (Source: National Bank of Ethiopia. 
http://www.nbe.gov.et/market/searchdailyexchange.html, accessed Nov 19, 2016) 
                                                 
22 An index (proxy for income) created for each household using principal components analysis from observed 
household assets including: material used to make floor, walls and roof of the main house, main type of toilet, main 
source of drinking water, main source of energy for cooking, and whether the household owned a car, bicycle, 
refrigerator, television set, mobile phone or a radio. 
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Table 5.2: Patients responses to the adherence questionnaire at T1 and T2 
  
Time 1 and Time 2 Time 1 group Time 2 group 
 
Question 
 
Responses to 
adherence 
questions (%)   
Responses to adherence questions (%) 
 
Responses to adherence questions (%) 
  
Observations All groups 
Observations 
Control (Kolfe 
Keranyo)n=192 
Intervention 
(Kirkos)n=209 Observations 
Control (Kolfe 
Keranyo)n=256 
Intervention 
(Kirkos)n=265 
1 Do you ever forget to take 
your medicine? 
922 Yes 279 (30) 
No 643 (70) 
401 Yes 60 (31) 
No 132 (69) 
Yes 76 (36) 
No 133 (64) 
521 Yes 66 (26) 
No 190 (74) 
Yes 77 (29) 
No 188 (71) 
2 Are you careless at times 
about taking your 
medicine? 
920 Yes 105 (11) 
No 815 (89) 
401 Yes 23 (12) 
No 169 (88) 
Yes 31 (15) 
No 178 (85) 
519 Yes 21 (8) 
No 233 (92) 
Yes 30 (11) 
No 235 (89) 
3 Sometimes if you feel 
worse, do you stop taking 
your medicines? 
920 Yes 78 (8) 
No 842 (92) 
401 Yes 14 (7) 
No 178 (93) 
Yes 19 (9) 
No 190 (91) 
519 Yes 21 (8) 
No 233 (92) 
Yes 24 (9) 
No 241 (91) 
4 Thinking about the last 
week. How often have you 
not taken your medicine? 
922 Never 776 (84) 
1-2 times 115 
(12) 
3-5 times 25 (3) 
>5 times 3 (1) 
401 Never 162 (84) 
1-2 times 22 (11) 
3-5 times 6 (3) 
>5 times 2 (1) 
Never 169 (81) 
1-2 times 33 (16) 
3-5 times 7 (3) 
>5 times 0 (0) 
521 Never 222 (87) 
1-2 times 27 (11) 
3-5 times 5 (2) 
>5 times 2 (1) 
Never 223 (84) 
1-2 times 33 (12) 
3-5 times 7 (3) 
>5 times 2 (1) 
5 Did you not take any of 
your medicine over the 
past weekend? 
914 Yes 48 (5) 
No 866 (95) 
401 Yes 9 (5) 
No 178 (95) 
Yes 15 (7) 
No 194 (93) 
513 Yes 13 (5) 
No 235 (95) 
Yes 11 (5) 
No 254 (95) 
6 Over the past 3 months, 
how many days have you 
not taken any medicine at 
all? 
921 ≤ 2 days 843 
(92) 
> 2 days 78 (8) 
401 ≤ 2 days 183 (95) 
> 2 days 9 (5) 
≤ 2 days 189 (90) 
> 2 days 20 (10) 
520 ≤ 2 days 227 (89) 
> 2 days 28 (11) 
≤ 2 days 244 (92) 
> 2 days 21 (8) 
N=926; 57 patients at baseline and 63 patients at follow-up were not on ART in this 
study 
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Table 5.3: Organizational and network characteristics of HIV service providers 
    Type of organization/facility by 
ownership 
Annual Budget (US$)   
Total 
Staff 
  
Refer-
ral ties 
  
Netw-
ork 
density Sub-city 
Time 
point Govt. NGO FBO Private Total Median Average Total Range 
Kirkos T1 3 5 3 13 24 34,107 45,702 685,535 642 - 151,772 1071 69 0.115 
T2 3 14 4 3 24 54,454 100,544 1,910,340 1,099 - 289,292 684 101 0.183 
Kolfe 
Keranyo 
T1 7 8 0 11 26 28,929 44,859 583,171 2,430 - 119,656 1245 101 0.155 
T2 7 5 1 12 25 225,647 344,407 5,510,505 2,893 - 1,967,183 1213 40 0.067 
Total   20 32 8 39 51   8,689,551  4213 311  
 
NGO: Non-governmental organization 
FBO: Faith-based organization 
Exchange rate: 2011 US$ 1 = Ethiopian Birr 17.2836 (Source: National Bank of Ethiopia. 
http://www.nbe.gov.et/market/searchdailyexchange.html, accessed Nov 19, 2016) 
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Table 5.4: Model results for path analysis for treatment delay and adherence 
  
Treatment 
delay on:  
Control at T1 Intervention at T1 Control at T2 Intervention at T2 
Estimate p-value Estimate p-value Estimate p-value Estimate p-value 
Age -0.02 0.28 -0.01 0.59 -0.02 0.10 -0.02 0.21 
Education 0.08 0.14 -0.06 0.32 0.04 0.51 0.09 0.11 
Married 0.45 0.01* 0.02 0.91 0.45 0.00** 0.01 0.93 
Wealth index 0.18 0.10 -0.02 0.79 -0.07 0.27 0.10 0.08 
Adherence on:         
Age 0.02 0.62 0.01 0.85 0.07 0.18 0.01 0.89 
Education -0.13 0.27 -0.18 0.18 -0.17 0.37 -0.24 0.23 
Married 0.05 0.89 0.72 0.08 0.25 0.68 0.66 0.23 
Wealth index -0.11 0.67 -0.28 0.11 0.35 0.18 -0.02 0.94 
Treatment 
delay 0.05 0.79 -0.25 0.19 -0.33 0.25 -0.66 0.03* 
Satisfaction 0.16 0.47 0.59 0.02* 0.65 0.12 0.98 0.01* 
N   191 209 252 266 
*p<0.05; **p<0.01 
 
 
Table 5.5: Estimates of effect of the intervention on treatment delay and adherence 
Outcome 
variable 
Control compared to intervention at 
T1 
Control compared to intervention at T2 
Estimate Odds Ratio p-value Estimate Odds Ratio p-value 
Treatment delay -0.22 0.80 0.07 -0.31 0.73 0.01* 
Adherence -0.41 - 0.09 -0.40 - 0.28 
 
*p<0.05 
 
 
Table 5.6: Difference in differences analysis for average number of days of treatment delay 
Time point Kolfe Keranyo (control) Kirkos (intervention) Difference in days 
Time 1 582 527 55 
Time 2 687 617 70 
Difference in days 105 90 15 
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Table 5.7: Model fit indices for the full model of treatment delay and adherence 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Model fit Index/measure Treatment delay and adherence 
Chi-Square  188.13 
Degrees of Freedom  144 
P-Value 0.01 
RMSEA estimate (90 Percent C.I.) 0.04(0.02 - 0.05) 
Probability RMSEA <= 0.05 0.95 
CFI 0.99 
TLI 0.99 
WRMR value 1.65 
N 926 
 92 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
       Source: Waste Management Threats to Human Health and Urban Aquatic Habitats – A Case       
       Study of Addis Ababa, Ethiopia23 
 
  
                                                 
23 Elias Mazhindu, Trynos Gumbo and Tendayi Gondo 
Figure 5.1: Sub cities of Addis Ababa, Ethiopia 
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Figure 5.2: Path diagram for treatment delay and adherence 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.3: The three stages of HIV infection – CD4  cells are destroyed by HIV 
Source: Stages of HIV infection – how does HIV progress in your body? https://www.aids.gov/hiv-
aids-basics/just-diagnosed-with-hiv-aids/hiv-in-your-body/stages-of-hiv/  
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Figure 5.4: Stages of HIV infection if left untreated 
Source: Stages of HIV infection – how does HIV progress in your body?https://www.aids.gov/hiv-
aids-basics/just-diagnosed-with-hiv-aids/hiv-in-your-body/stages-of-hiv/  
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a 
Mediator (MV) 
Outcome variable (DV)   Independent variable (IV)  
b 
c 
A variable is a mediator if: 
(a) The IV and MV are correlated. 
(b) The MV and DV are correlated. 
(c) The IV and DV are correlated, but not if the MV is controlled for. 
Figure 5.5: Mediational model adopted from Baron & Kenny (1986) 
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 DISCUSSION CHAPTER 6.
 
6.1 Summary of findings 
Aim 1: Measurement invariance of HIV treatment adherence and quality of life scales 
among HIV positive women in Ethiopia 
 
Studies have not examined measurement invariance of the Simplified Medication Adherence 
Questionnaire and World Health Organization Quality of Life – HIV 31 BREF scales for 
measurement of treatment adherence and quality of life among HIV/AIDS patients in Ethiopia. 
The objective of this study was to assess whether the same latent constructs of antiretroviral 
treatment adherence and quality of life were measured across two patient groups at two time points. 
Multiple group confirmatory factor analysis was conducted among 926 HIV positive women in 
Ethiopia. Measurement invariance was found for factor loadings, observed item intercepts and 
factor variances when comparing adherence among participants in two treatment networks at 
baseline and follow-up. Findings suggest similarity in the levels of observed responses for adherence 
across intervention and non- intervention groups at two time points that would be expected for 
patients with similar adherence latent factors scores. The adherence questionnaire exhibited stability 
across groups. Average scores obtained using the adherence questionnaire can, therefore, be 
compared across the groups of HIV-positive patients. However, these similarities are not observed 
in latent factor scores for quality of life, suggesting significant measurement, cultural, or 
developmental differences between patient groups. Therefore, average scores obtained from this 
questionnaire cannot be compared across groups. Interventionists and researchers should be aware 
of these differences between groups when implementing interventions for HIV/AIDS services 
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across patient groups that may have cultural and developmental differences. Further, researchers and 
interventionists should pay attention to measurement bias that may limit accuracy of patient-
reported adherence and quality of life.  
 
Aim 2: An exploration of the effects of organizational networks and patient characteristics 
on medication adherence among HIV+ women in Ethiopia 
 
HIV/AIDS continues to cause significant socio-economic burden on patients and their families, 
especially in the sub-Saharan Africa region where more than 25 million people are living with the 
virus, of whom 12 million are accessing antiretroviral therapy. The need for rapid and inexpensive 
interventions that improve adherence to antiretroviral therapy and quality of life of HIV-positive 
people is vital. In a quasi-experimental study in two sub-cities of Addis Ababa, among 926 HIV-
positive women who were receiving antiretroviral therapy and other treatment support services from 
51 health facilities there, MEASURE Evaluation implemented a healthcare system-level intervention 
in the experimental but not in the control sub-city. Structural equation models were used to assess 
associations between adherence and quality of life and demographic characteristics of patients and to 
compare levels of these two latent outcomes before and after the intervention. Findings suggest that 
the health system strengthening intervention did not improve adherence to antiretroviral therapy 
and that patient characteristics had no effect on adherence levels across groups. Health system-level 
interventions that increase interactions and referrals between health facilities aiming to increase 
access to ART and other health services among HIV-positive women alone are insufficient for 
significant improvements in long-term adherence. To accomplish significant improvement to long-
term adherence, a program requires multi-level interventions with sufficient components, such as 
found in the WHO five-dimensions of adherence. 
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Aim 3: The missing link between HIV/AIDS referral networks and positive health 
outcomes among HIV-positive women in Ethiopia 
 
Initiation and retention of HIV/AIDS patients on antiretroviral therapy are major goals of the 
UNAIDS Fast-Track Initiative and of the Ethiopian government. Timely antiretroviral therapy 
initiation, adherence to therapy and satisfaction with HIV/AIDS care are essential to the success of 
the UNAIDS and the global public health community and governments. Enhancing these outcomes 
among ensures return on HIV/AIDS investments by local communities, the public health 
community and governments. Rapid and affordable interventions that improve organizational 
referral networks have been shown to significantly improve patient-reported outcomes, but the 
pathways of these effects are poorly understood. The objective of this study was to use structural 
equation models to assess direct and indirect effects of organizational referral networks and patient-
related factors on patient-reported delay in initiation of antiretroviral therapy and adherence among 
926 HIV-positive women who were receiving antiretroviral therapy and other treatment support 
services from 51 organizations and health facilities. It also assessed the effect of enhanced speed of 
initiation of antiretroviral therapy on adherence. Findings suggest that the intervention enhanced 
speed of antiretroviral initiation. In addition, enhanced antiretroviral initiation improved adherence. 
Finally, evidence suggests that improved satisfaction with HIV/AIDS care improves adherence. 
Rapid, affordable and non-complex system-level intervention to improve inter-organizational 
coordination, interactions and referral of HIV/AIDS patients can have a positive impact on patient 
outcomes through quicker initiation of antiretroviral therapy. Finding similar ways to quickly 
improve adherence through health system- or organizational-level interventions, in cognizance of 
the WHO’s multi-level model of adherence may have positive impact on adherence to antiretroviral 
therapy. 
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6.2 Implications for policy and practice  
Accurate assessment of adherence and quality of life is an essential priority for the global 
HIV/AIDS community. Accurate measurement of these latent outcomes in low-income settings is 
likely to lead to policies that can create effective targeted interventions. My findings may inform 
adoption of standardized scales of adherence and quality of life. They also raise pertinent issues to 
consider when using these scales. Specifically, I showed that the adherence scale is invariant to 
measurement bias and cultural and developmental differences, which may exist between groups of 
patients, whereas the quality of life scale was non-invariant. Non-invariance adversely affects 
resultant policies because it results from inaccurate measurement of the intended latent construct. It 
can lead to ineffective policies about how to improve adherence and quality of life in different sub-
groups of the population. 
 
These findings are essential because the two scales are commonly used to assess levels of adherence 
and quality of life among HIV/AIDS patients in many settings, where socio-economic, demographic 
and cultural differences between population groups, may affect understanding, interpretation and 
responses to questions. Differences in understanding, interpretation and response to questions in 
the scales, together with measurement bias, are some of the causes of measurement non-invariance. 
Measurement bias, which may be caused by systematic under- or over-reporting may also cause non-
invariance. It is essential that scales used to collect data for national or regional policy formulation 
are accurate and gather comparable results. Various strategies can be used to improve understanding, 
facilitate accurate interpretation and response and reduce measurement bias. First, researchers and 
interventionists can ascertain that measurement invariance for the scale they intend to use has been 
conducted in a comparable or similar setting, before beginning data collection. Second, in order to 
reduce measurement bias, strategies for increasing validity and reliability of data can be adopted 
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before and during data collection. Such strategies include ensuring: adequate training of data 
collectors, test-retest, inter-rater and internal consistency reliability and face, and construct validity of 
data. Whereas this process may be time-consuming and costly, it facilitates confidence in findings, 
conclusions and policy recommendations.  
 
Likewise, increasing timely access and adherence to ART is essential for HIV-positive people and to 
the achievement of the UNAIDS 90-90-90 and 95-95-95 cascade goals, also known as UNAIDS 
FastTrack Initiative. To achieve these goals, the global public health community needs to develop 
interventions that can facilitate timely access to ART and increase adherence. I demonstrated that a 
health system-level intervention that increases inter-organizational ties between service providers in 
a given geographical area can reduce delay in ART initiation. Thomas et al. (2015) demonstrated that 
increased ties between providers also increase satisfaction (Thomas J. , Reynolds, Alterescu, Bevc, & 
Tsegaye, 2015). I also demonstrated that reduced delay and increased satisfaction with HIV/AIDS 
care improve adherence. The WHO adherence model suggests that adherence can be improved by 
intervening in five-multi-level factors (WHO, 2003).  
 
The intervention that I assessed intervened at the health-system level, and was associated with early 
receipt of ART among patients in the intervention network. To be adherent to ART, patients first 
need to have the antiretroviral drugs. Thus, an intervention that facilitates faster access to drugs is 
geared towards improving adherence. Adherence further facilitates achievement of the third 90 or 95 
in the UNAIDS FastTrack Initiative, whereby those with HIV infection have undetectable or 
suppressed levels of viral load (UNAIDS, 2014). The intervention was non-complex, rapid, 
inexpensive and can be highly replicable in low-income settings. The intervention utilizes local and 
existing resources within the network to increase access to ART. Interventionists can adopt this 
 101 
 
strategy to increase access to ART in various similar settings. However, to increase adherence, more 
research is needed to explore cost-effective, rapid and feasible interventions that can significantly 
improve relevant socio-economic, therapy, patient and condition-related factors among HIV/AIDS 
patients.  
 
6.3 Knowledge gaps and future directions 
Organizational referral networks are under-studied worldwide, and even less so in sub-Saharan 
Africa settings. This study is the first to look at direct and indirect pathways between network 
characteristics and patient-level health outcomes. The results will be relevant for HIV treatment 
policy interventions in Ethiopia and beyond. They will also inform methods used in studies of 
referral networks. Referral network studies and network strengthening interventions have the 
potential to increase access to care for many diseases in low-resource countries where medical 
supplies, laboratories, equipment and services are only found in certain organizations in some 
geographical locations. Whereas organizational networks may be an efficient way to provide 
increased access to healthcare services to more people, no work has been done to find out the 
optimal number of organizations or referral pattern that should be in a referral network. I intend to 
pursue research that will contribute to furthering knowledge in this area. 
 
Innovative research designs to address long-term ART adherence are necessary, especially because it 
is a lifetime treatment. I intend to pursue longitudinal adherence research using factorial 
experimental designs within referral network contexts to determine necessary and sufficient 
components of the WHO’s adherence model that can improve adherence to the 95 percent 
threshold required for optimal ART effectiveness. Creating adherence interventions with networks 
of service providers is a potentially affordable strategy for providing care to people in these settings, 
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because it can optimize benefits from already deployed resources within individual organizations. 
The WHO has created a working group that seeks to address long-term adherence (WHO, 2001). I 
intend to find ways to join this group as a researcher and contribute to their efforts, in the United 
States and in sub-Saharan Africa.  
 
In addition, many sub-Saharan African governments have resource limitations and competing 
budgetary needs, meaning that health facilities can only offer certain services. This calls for close, 
regular and planned interaction between organizations providing those services in order to ensure 
patients can access them. My future goal is to improve efficiency in healthcare service, healthcare 
quality and access through the advantages of individual, organizational and health system networks 
in low-resource settings through research and interventions, applying surveys and psychometric 
assessments with a focus on chronic illnesses. 
 
6.4 Conclusions 
The overall objectives of this dissertation were to assess measurement invariance of the commonly 
used scales of adherence and quality of life and to assess the effect of the system-level referral 
network intervention on delay in ART initiation and adherence among HIV-positive Ethiopian 
women in Addis Ababa, Ethiopia.  
 
Accurate measurement of adherence to ART and quality of life is necessary for effective evaluation 
of HIV/AIDS care policy and programs aimed achieving the UNAIDS 90-90-90 goals. Patient-
reported latent outcomes such as adherence and quality of life are sensitive to measurement bias, 
cultural and developmental differences, which may influence effectiveness of resultant policies. This 
requires measurement invariance testing of standardized scales of adherence and quality of life, 
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which indicates whether average scores obtained from the scales can be compared across patient-
groups. Measurement invariance testing can help policy-makers, interventionists and researchers 
using such scales be aware of potential measurement bias, cultural and developmental issues, which 
may render scores from such scales incomparable across patient-groups. In addition, it creates 
confidence in policy recommendations generated from data collected using scales which have been 
tested and found to be invariant to measurement bias, cultural and developmental differences. I 
demonstrated that the Simplified Medication Adherence Questionnaire was invariant, therefore, 
average scores obtained from it can be compared across patient-groups in this Ethiopian sample. 
However, the WHOQOL-BREF exhibited non-invariance, thus its average scores could not be 
compared across groups. Findings from the WHOQOL-BREF suggested presence of one or 
combination of systematic under- or over-reporting, significant cultural or developmental 
differences between patient-groups in this sample.  
 
Increasing access to antiretroviral therapy and improving adherence are also goals of the UNAIDS 
90-90-90 initiative. I demonstrated that the health system-level referral network intervention, which 
improved inter-organizational ties between providers in the intervention network reduced delay in 
ART initiation, but did not improve adherence. Further, I demonstrated that reduced ART delay and 
increased satisfaction with HIV/AIDS care improved adherence. Therefore, improvement in inter-
organizational ties also, known as improved network density, is a necessary but insufficient strategy 
for improved adherence in low-income settings, as depicted in the WHO model. Reducing treatment 
delay should be one of the goals of any intervention that seeks to improve access to ART and 
adherence among HIV-positive patients in low-income settings. To improve adherence, an 
intervention should significantly improve the patient’s condition-, individual-, therapy- and 
socioeconomic-, in addition to, health system-related factors.  
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APPENDIX 1: WHOQOL-HIV BREF QUESTIONNAIRE 
MENTAL HEALTH: EVIDENCE AND RESEARCH DEPARTMENT OF MENTAL HEALTH 
AND SUBSTANCE DEPENDENCE WORLD HEALTH ORGANIZATION GENEVA 
 
Instructions  
 
This assessment asks how you feel about your quality of life, health, or other areas of your life. Please answer all the 
questions. If you are unsure about which response to give to a question, please choose the one that appears most 
appropriate. This can often be your first response. Please keep in mind your standards, hopes, pleasures and concerns. 
We ask that you think about your life in the last two weeks. For example, thinking about the last two weeks, a question 
might ask:  
 
  
Not at all A little 
A moderate 
amount 
Very much Extremely 
11 (F5.3) 
How well are you able to 
concentrate?  
1 2 3 4 5 
 
You should circle the number that best fits how well are you able to concentrate over the last two weeks. So you would 
circle the number 4 if you were able to concentrate very much. You would circle number 1 if you were not able to 
concentrate at all in the last two weeks. 
 
Please read each question, assess your feelings, and circle the number on the scale for each question that gives 
the best answer for you.  
 
  
Very poor Poor 
Neither poor 
nor good 
Good Very good 
1(G1) 
How would you rate your quality 
of life?  
1 2 3 4 5 
  
Very 
dissatisfied 
Dissatisfied 
Neither 
satisfied nor 
dissatisfied 
Satisfied 
Very 
satisfied 
2 (G4) 
How satisfied are you with your 
health?  
1 2 3 4 5 
 
The following questions ask about how much you have experienced certain things in the last two weeks.  
 
  
Not at all A little 
A moderate 
amount 
Very much 
An extreme 
amount 
3 (F1.4) 
To what extent do you feel that 
physical pain prevents you from 
doing what you need to do?  
1 2 3 4 5 
4 (F50.1) 
How much are you bothered by 
any physical problems related to 
your HIV infection?  
1 2 3 4 5 
5 (F11.3) 
How much do you need any 
medical treatment to function in 
your daily life?  
1 2 3 4 5 
6 (F4.1) How much do you enjoy life?  1 2 3 4 5 
7 (F24.2) 
To what extent do you feel your 
life to be meaningful?  
1 2 3 4 5 
8 (F52.2) 
To what extent are you bothered 
by people blaming you for your 
HIV status  
1 2 3 4 5 
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9 (F53.4) How much do you fear the future?  1 2 3 4 5 
10 (F54.1) 
How much do you worry about 
death?  
1 2 3 4 5 
  Not at all A little 
A moderate 
amount 
Very much Extremely 
11 (F5.3) 
How well are you able to 
concentrate?  
1 2 3 4 5 
12 (F16.1) 
How safe do you feel in your daily 
life?  
1 2 3 4 5 
13 (F22.1) 
How healthy is your physical 
environment?  
1 2 3 4 5 
 
The following questions ask about how completely you experience or were able to do certain things in the last two 
weeks.  
 
  
Not at all A little Moderately Mostly Completely 
14 (F2.1) 
Do you have enough energy for 
everyday life?  
1 2 3 4 5 
15 (F7.1) 
Are you able to accept your bodily 
appearance?  
1 2 3 4 5 
16 (F18.1) 
Have you enough money to meet 
your needs?  
1 2 3 4 5 
17 (F51.1) 
To what extent do you feel 
accepted by the people you know?  
1 2 3 4 5 
18 (F20.1) 
How available to you is the 
information that you need in your 
day-to-day life?  
1 2 3 4 5 
19 (F21.1) 
To what extent do you have the 
opportunity for leisure activities? 
1 2 3 4 5 
  Very poor Poor 
Neither poor 
nor good 
Good Very good 
20 (F9.1) 
How well are you able to get 
around?  
1 2 3 4 5 
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The following questions ask you how good or satisfied you have felt about various aspects of your life over the last two 
weeks.  
 
  
Very 
dissatisfied 
Dissatisfied 
Neither 
satisfied nor 
dissatisfied 
Satisfied 
Very 
satisfied 
21 (F3.3) 
How satisfied are you with your 
sleep?  
1 2 3 4 5 
22 (F10.3) 
How satisfied are you with your 
ability to perform your daily living 
activities?  
1 2 3 4 5 
23 (F12.4) 
How satisfied are you with your 
capacity for work?  
1 2 3 4 5 
24 (F6.3) 
How satisfied are you with 
yourself?  
1 2 3 4 5 
25 (F13.3) 
How satisfied are you with your 
personal relationships?  
1 2 3 4 5 
26 (F15.3) 
How satisfied are you with your 
sex life?  
1 2 3 4 5 
27 (F14.4) 
How satisfied are you with the 
support you get from your 
friends?  
1 2 3 4 5 
28 (F17.3) 
How satisfied are you with the 
conditions of your living place?  
1 2 3 4 5 
29 (F19.3) 
How satisfied are you with your 
access to health services?  
1 2 3 4 5 
30 (F23.3) 
How satisfied are you with your 
transport?  
1 2 3 4 5 
 
The following question refers to how often you have felt or experienced certain things in the last two weeks.  
 
  
Never Seldom Quite often Very often Always 
31 (F8.1) 
How often do you have negative 
feelings such as blue mood, 
despair, anxiety, depression?  
1 2 3 4 5 
 
SCORING OF THE WHOQOL 31-BREF  
 
The WHOQOL-HIV BREF produces six domain scores. Whereas the WHOQOL-100 has four items to present each 
facet, the WHOQOL-HIV BREF has only one item. Included in these, there are two items that examine General quality 
of life: question 1 asks about an individual’s overall perception of quality of life and question 2 asks about an individual’s 
overall perception of his or her health. Hence there are 31 items, representing the 30 facets. Five of these facets are 
specific to HIV/AIDS.  
 
Like the WHOQOL-100, individual items are rated on a 5 point Likert scale where 1 indicates low, negative perceptions 
and 5 indicates high, positive perceptions. F or example, an item in the positive feeling facet asks “How much do you 
enjoy life?” and the available responses are 1 (not at all), 2 (a little) 3 (a moderate amount), 4 (very much) and 5 (an 
extreme amount). As such, domain and facet scores are scaled in a positive direction w here higher scores denote higher 
quality of life. Some facets (Pain and Discomfort, Negative Feelings, Dependence on Medication, Death and Dying) are 
not scaled in a positive direction, meaning that for these facets higher scores do not denote higher quality of life. These 
need to be recoded so that high scores reflect better QOL. Items are organized by response scale (capacity, frequency, 
intensity or satisfaction). Instructions for calculation of scores are given below. These follow the syntax file, which can 
be obtained from the WHOQOL HIV Coordinator, Mental Health: Evidence and Research, Department of Mental 
Health and Substance Dependence, CH-1211 Geneva 27, Switzerland.  
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SCORING PROCEDURE  
 
First, all scores need to be checked that they are in the appropriate range (between 1 and 5).  
 
Check all items from assessment have a range of 1-5  
Steps  
SPSS syntax for carrying out data checking, cleaning and computing total 
scores  
Check all 26 items from 
assessment have a range of 1-5  
RECODE Q1 Q2 Q3 Q4 Q5 Q6 Q7 Q8 Q9 Q10 Q11 Q12 Q13 Q14 Q15 Q16 Q17 
Q18 Q19 Q20 Q21 Q22 Q23 Q24 Q25 Q26 Q27 Q28 Q29 Q30 Q31  
(1=1) (2=2) (3=3) (4=4) (5=5) (ELSE=SYSMIS). 
 
(This recodes all data outside the range 1-5 to system missing.)  
 
Domain scores are scaled in a positive direction w here higher scores denote higher quality of life. Some items are not 
scaled in a positive direction (e.g. Pain and Discomfort, Negative Feelings, Dependence on Medication, Death and 
Dying), meaning that for these facets higher scores do not denote higher quality of life. These need to be recoded so that 
high scores reflect better QOL. Domain scores are scaled in a positive direction (i.e. higher scores denote higher quality 
of life). Instructions for calculation of scores are given below. 
 
Reverse negatively phrased items  
 
 
The mean score of items within each domain is used to calculate the domain score. Mean scores are then multiplied by 4 
in order to make domain scores comparable with the scores used in the WHOQOL, so that scores range between 4 and 
20.  
 
Calculate Domain Scores 
 
The WHOQOL-BREF can also be scored by hand. To do this, negative scores must be reversed. Hence the formula 6 - 
x is used. This will ensure, for example, that if someone reports fearing the future a great deal (5), subtracting the score 
by six, will automatically recode the item to 1. Instructions for this are provided on the first page of the instrument.  
 
 
 
  
Compute domain scores  Domain 1 (physical) = (Q3 + Q4 + Q14 + Q21)/4 * 4 
Domain 2 (psychological) = (Q6 + Q11 + Q15 + Q24 + Q31)/5 *4 
Domain 3 (level of independence) = (Q5 + Q22 + Q23 + Q20)/4 * 4 
Domain 4 (social relationships) = (Q27 +Q26 + Q25 + Q17)/4*4 
Domain 5 (environment) =(Q12+ Q13+ Q16+ Q18+ Q19+Q28+Q29+Q30)/8*4 
Domain 6 (spirituality/religion/personal beliefs) = (Q7 + Q8 + Q9+ Q10)/4 *4 
 
(These equations calculate the domain scores. All scores are multiplied by 4 so as to be 
directly comparable with scores derived from the WHOQOL-100)  
Reverse 6 negatively phrased 
items  
RECODE Q3 Q4 Q5 Q8 Q9 Q10 Q31 (1=5) (2=4) (3=3) (4=2) (5=1). 
(This transforms negatively framed questions to positively framed questions.)  
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APPENDIX 2: SIMPLIFIED MEDICATION ADHERENCE QUESTIONNAIRE 
 
  
Yes 
 
 
No 
 
 
 
1. Do you ever forget to take your 
medicine? 
  
2. Are you careless at times about taking 
your medicine? 
  
3. Sometimes if you feel worse, do you 
stop taking your medicines? 
  
5. Did you not take any of your medicine 
over the past weekend? 
  
  
Never 
 
 
1 - 2 times 
 
3 - 5 times 
 
6 - 10 times 
 
> 10 times 
4. Thinking about the last week. How 
often have you not taken your medicine? 
     
  
≤ 2 days 
 
> 2 days 
 
 
6. Over the past 3 months, how many days 
have you not taken any medicine at all? 
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